epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Paxlovid

nirmatrelvir and ritonavir

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Significant Drug Interactions

ritonavir, a strong CYP3A inhibitor, may cause incr. exposure of certain medications, resulting in potential severe, life-threatening or fatal events; review all medications to assess potential drug interactions and determine if dose adjustment, interruption, or additional monitoring required; consider benefit of reduced hospitalization and death and risk of appropriate drug interaction management

Adult Dosing .

Dosage forms:  TAB (5-day pack): nirmatrelvir 150 mg x20 and ritonavir 100 mg x10; TAB (moderate renal impairment 5-day pack): nirmatrelvir 150 mg x10 and ritonavir 100 mg x10; TAB (severe renal impairment 5-day pack): nirmatrelvir 150 mg x6 and ritonavir 100 mg x5

COVID-19, mild-moderate

[1 dose PO bid x5 days]
Start: ASAP within 5 days of symptom onset; Info: for patients at high risk for severe disease including hospitalization or death; 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir; do not cut/crush/chew tab

renal dosing

[see below]
eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid; eGFR <30: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days
HD: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days, on dialysis days administer after dialysis; no supplement; PD: not defined

hepatic dosing

[see below]
Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Peds Dosing .

Dosage forms:  TAB (5-day pack): nirmatrelvir 150 mg x20 and ritonavir 100 mg x10; TAB (moderate renal impairment 5-day pack): nirmatrelvir 150 mg x10 and ritonavir 100 mg x10; TAB (severe renal impairment 5-day pack): nirmatrelvir 150 mg x6 and ritonavir 100 mg x5

Special Note

[FDA emergency use authorization (EUA)]
Info: for mild-moderate COVID-19 in patients at high risk for severe disease including hospitalization or death; available from Pfizer Inc. or authorized distributors as directed by US government; for clinical trial eligibility and enrollment info, check www.clinicaltrials.gov
[mandatory reporting for EUA]
Info: serious medication errors and adverse events must be reported to FDA MedWatch (www.fda.gov/medwatch/report.htm or 1-800-FDA-1088) and Pfizer Inc. (1-800-438-1985)

COVID-19, mild-moderate

[12 yo and older, >40 kg]
Dose: 1 dose PO bid x5 days; Start: ASAP within 5 days of symptom onset; Info: for patients at high risk for severe disease including hospitalization or death; 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir; do not cut/crush/chew tab

renal dosing

[see below]
eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid; eGFR <30: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days
HD: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days, on dialysis days administer after dialysis; no supplement; PD: not defined

hepatic dosing

[see below]
Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@38a86d78
  • hypersensitivity to drug or ingredient
  • caution: eGFR <60
  • caution: hepatic disease
  • caution: COVID-19 infection and untreated HIV infection, concurrent

Drug Interactions .

Overview

nirmatrelvir

SARS-CoV-2 main protease inhibitor

Interaction Characteristics:
  • CYP3A4 substrate
Other Info
  • patients on ritonavir- or cobicistat-containing HIV or HCV regimens may continue their tx as indicated

ritonavir

CYP3A4 booster; HIV protease inhibitor

Interaction Characteristics:
  • CYP3A4 substrate
  • P-gp substrate
  • CYP2D6 inhibitor, weak
  • CYP3A4 inhibitor, strong
  • BCRP inhibitor
  • MRP2 inhibitor
  • OATP1B1 inhibitor, moderate
  • OATP1B3 inhibitor, moderate
  • P-gp inhibitor, moderate
  • CYP1A2 inducer, moderate
  • CYP2B6 inducer, weak
  • CYP2C8 inducer, weak
  • CYP2C9 inducer, weak
  • CYP2C19 inducer, weak
  • CYP3A4 inducer, weak
  • UGT1A1 inducer
  • UGT1A4 inducer
  • UGT1A9 inducer
  • UGT2B4 inducer
  • UGT2B7 inducer
  • affected by altered fat absorption
  • delays atrioventricular conduction
  • hyperglycemic effects
  • hyperuricemic effects
  • interferes w/ gene therapy

Contraindicated

  • alfuzosin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alfuzosin
    1 interaction

    Contraindicated

    ritonavir + alfuzosin

    contraindicated: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • amiodarone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    amiodarone
    1 interaction

    Contraindicated

    ritonavir + amiodarone

    contraindicated: combo may incr. amiodarone levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • apalutamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    apalutamide
    2 interactions

    Contraindicated

    nirmatrelvir + apalutamide

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + apalutamide

    contraindicated: combo may decr. ritonavir levels, efficacy; may incr. apalutamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced, P-gp-mediated transport induced; hepatic metabolism inhibited)

  • butalbital
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    butalbital
    2 interactions

    Contraindicated

    nirmatrelvir + butalbital

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    ritonavir + butalbital

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • carbamazepine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    carbamazepine
    2 interactions

    Contraindicated

    nirmatrelvir + carbamazepine

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + carbamazepine

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative or monitor carbamazepine levels, HR, consider monitoring ECG: combo may decr. ritonavir levels, efficacy; may incr. carbamazepine levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism induced, P-gp-mediated transport induced; hepatic metabolism inhibited, additive effects)

  • cisapride
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cisapride
    1 interaction

    Contraindicated

    ritonavir + cisapride

    contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • colchicine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    colchicine
    1 interaction

    Contraindicated

    ritonavir + colchicine

    CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after ritonavir use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • conivaptan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    conivaptan
    1 interaction

    Contraindicated

    ritonavir + conivaptan

    contraindicated: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

  • dihydroergotamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dihydroergotamine
    1 interaction

    Contraindicated

    ritonavir + dihydroergotamine

    contraindicated: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • domperidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    domperidone
    1 interaction

    Contraindicated

    ritonavir + domperidone

    contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dronedarone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dronedarone
    1 interaction

    Contraindicated

    ritonavir + dronedarone

    contraindicated: combo may incr. dronedarone levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • elagolix
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elagolix
    2 interactions

    Contraindicated

    ritonavir + elagolix

    contraindicated: combo may incr. elagolix levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited, hepatic transport inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + elagolix

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • eletriptan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eletriptan
    1 interaction

    Contraindicated

    ritonavir + eletriptan

    contraindicated w/in 72h of use: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • eliglustat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eliglustat
    1 interaction

    Contraindicated

    ritonavir + eliglustat

    CYP2D6 EM: monitor ECG, HR; decr. eliglustat dose to 84 mg qd; CYP2D6 IM OR PM: contraindicated: combo may incr. eliglustat levels, risk of PR or QT prolongation, AV block, bradycardia, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • encorafenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    encorafenib
    2 interactions

    Contraindicated

    nirmatrelvir + encorafenib

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    ritonavir + encorafenib

    avoid combo if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative or monitor ECG; decr. encorafenib 450 mg dose to 150 mg, decr. 300 mg dose to 75 mg, decr. 225 mg dose to 75 mg, and decr. 150 mg dose to 75 mg: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • enzalutamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    enzalutamide
    2 interactions

    Contraindicated

    nirmatrelvir + enzalutamide

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + enzalutamide

    contraindicated if ritonavir administered with nirmatrelvir; otherwise, use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • eplerenone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eplerenone
    1 interaction

    Contraindicated

    ritonavir + eplerenone

    contraindicated: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • ergotamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ergotamine
    1 interaction

    Contraindicated

    ritonavir + ergotamine

    contraindicated: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • finerenone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    finerenone
    1 interaction

    Contraindicated

    ritonavir + finerenone

    contraindicated: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • flecainide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    flecainide
    1 interaction

    Contraindicated

    ritonavir + flecainide

    contraindicated: combo may incr. flecainide levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • flibanserin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    flibanserin
    1 interaction

    Contraindicated

    ritonavir + flibanserin

    contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

  • fosphenytoin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fosphenytoin
    2 interactions

    Contraindicated

    nirmatrelvir + fosphenytoin

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + fosphenytoin

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative or monitor phenytoin levels, HR, consider monitoring ECG: combo may decr. levels of both drugs, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metabolism induced, P-gp-mediated transport induced; additive effects)

  • gepirone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    gepirone
    1 interaction

    Contraindicated

    ritonavir + gepirone

    contraindicated: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • grazoprevir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    grazoprevir
    1 interaction

    Contraindicated

    ritonavir + grazoprevir

    contraindicated: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • isavuconazonium
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    isavuconazonium
    1 interaction

    Contraindicated

    ritonavir + isavuconazonium

    contraindicated w/ ritonavir doses of 800 mg/day or greater; otherwise, caution advised: combo may incr. isavuconazole levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • ivabradine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ivabradine
    1 interaction

    Contraindicated

    ritonavir + ivabradine

    contraindicated: combo may incr. ivabradine levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ivosidenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ivosidenib
    2 interactions

    Contraindicated

    nirmatrelvir + ivosidenib

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    ritonavir + ivosidenib

    avoid combo if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative or monitor ECG, decr. ivosidenib dose to 250 mg PO qd: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • lomitapide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lomitapide
    1 interaction

    Contraindicated

    ritonavir + lomitapide

    contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lonafarnib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lonafarnib
    1 interaction

    Contraindicated

    ritonavir + lonafarnib

    contraindicated: combo may incr. or decr. lonafarnib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • lovastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lovastatin
    1 interaction

    Contraindicated

    ritonavir + lovastatin

    contraindicated; D/C lovastatin at least 12h before nirmatrelvir/ritonavir initiation and x5 day after nirmatrelvir/ritonavir tx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, hepatic transport inhibited, P-gp-mediated transport inhibited)

  • lumacaftor/ivacaftor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lumacaftor/ ivacaftor
    2 interactions

    Contraindicated

    nirmatrelvir + lumacaftor/ ivacaftor

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + lumacaftor/ ivacaftor

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative: combo may decr. ritonavir levels, efficacy; may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism induced, P-gp-mediated transport possibly induced; hepatic metabolism inhibited)

  • lurasidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lurasidone
    1 interaction

    Contraindicated

    ritonavir + lurasidone

    contraindicated: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • methylergonovine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    methylergonovine
    1 interaction

    Contraindicated

    ritonavir + methylergonovine

    contraindicated: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • midazolam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    midazolam
    1 interaction

    Contraindicated

    ritonavir + midazolam

    ORAL MIDAZOLAM: contraindicated; NASAL MIDAZOLAM: avoid combo; INJ MIDAZOLAM: monitor respiratory rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • mitotane
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mitotane
    2 interactions

    Contraindicated

    nirmatrelvir + mitotane

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    ritonavir + mitotane

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • nafcillin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nafcillin
    2 interactions

    Contraindicated

    ritonavir + nafcillin

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    nirmatrelvir + nafcillin

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • naloxegol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    naloxegol
    1 interaction

    Contraindicated

    ritonavir + naloxegol

    contraindicated: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

  • pacritinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pacritinib
    2 interactions

    Contraindicated

    ritonavir + pacritinib

    contraindicated: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Avoid/Use Alternative

    nirmatrelvir + pacritinib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • pentobarbital
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pentobarbital
    2 interactions

    Contraindicated

    nirmatrelvir + pentobarbital

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Avoid/Use Alternative

    ritonavir + pentobarbital

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • phenobarbital
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    phenobarbital
    2 interactions

    Contraindicated

    nirmatrelvir + phenobarbital

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + phenobarbital

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

  • phenytoin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    phenytoin
    2 interactions

    Contraindicated

    nirmatrelvir + phenytoin

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + phenytoin

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative or monitor phenytoin levels, HR: combo may decr. levels of both drugs, efficacy; may incr. risk of bradycardia (hepatic metabolism induced, P-gp-mediated transport induced; additive effects)

  • pimozide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pimozide
    1 interaction

    Contraindicated

    ritonavir + pimozide

    contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • primidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    primidone
    2 interactions

    Contraindicated

    nirmatrelvir + primidone

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + primidone

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

  • propafenone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    propafenone
    1 interaction

    Contraindicated

    ritonavir + propafenone

    contraindicated: combo may incr. propafenone levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quinidine (antiarrhythmic)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Contraindicated

    ritonavir + quinidine (antiarrhythmic)

    contraindicated: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • ranolazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ranolazine
    1 interaction

    Contraindicated

    ritonavir + ranolazine

    contraindicated: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • rifampin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rifampin
    2 interactions

    Contraindicated

    nirmatrelvir + rifampin

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + rifampin

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, consider alternative: combo may decr. ritonavir levels, efficacy; may incr. rifampin levels, risk of adverse effects; combo of ritonavir-boosted protease inhibitor and rifampin may result in GI intolerance, hepatotoxicity (hepatic metabolism induced, P-gp-mediated transport induced; hepatic transport inhibited; mechanism unknown)

  • rifapentine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rifapentine
    2 interactions

    Contraindicated

    nirmatrelvir + rifapentine

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + rifapentine

    contraindicated if ritonavir admin. w/ nirmatrelvir; otherwise, use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

  • sildenafil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sildenafil
    1 interaction

    Contraindicated

    ritonavir + sildenafil

    PULMONARY HTN: contraindicated; ERECTILE DYSFUNCTION: monitor BP; adjust max sildenafil dose to 25 mg/48h: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

  • silodosin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    silodosin
    1 interaction

    Contraindicated

    ritonavir + silodosin

    contraindicated: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • simvastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    simvastatin
    1 interaction

    Contraindicated

    ritonavir + simvastatin

    contraindicated; D/C simvastatin at least 12h before nirmatrelvir/ritonavir initiation and x5 day after nirmatrelvir/ritonavir tx: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • St. John's wort
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    St. John's wort
    2 interactions

    Contraindicated

    nirmatrelvir + St. John's wort

    contraindicated: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + St. John's wort

    contraindicated: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

  • suzetrigine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    suzetrigine
    2 interactions

    Contraindicated

    ritonavir + suzetrigine

    contraindicated: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + suzetrigine

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • thioridazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    thioridazine
    1 interaction

    Contraindicated

    ritonavir + thioridazine

    contraindicated: combo may incr. or decr. thioridazine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • tolvaptan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tolvaptan
    1 interaction

    Contraindicated

    ritonavir + tolvaptan

    contraindicated: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • triazolam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    triazolam
    1 interaction

    Contraindicated

    ritonavir + triazolam

    contraindicated: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ubrogepant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ubrogepant
    1 interaction

    Contraindicated

    ritonavir + ubrogepant

    contraindicated: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • venetoclax
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    venetoclax
    1 interaction

    Contraindicated

    ritonavir + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • voclosporin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    voclosporin
    1 interaction

    Contraindicated

    ritonavir + voclosporin

    contraindicated: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • voriconazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    voriconazole
    1 interaction

    Contraindicated

    ritonavir + voriconazole

    contraindicated with ritonavir 400 mg bid or greater; avoid combo if ritonavir administered with nirmatrelvir; otherwise, use alternative or monitor breakthrough fungal infection: combo may decr. voriconazole levels, efficacy (hepatic metabolism induced)

Avoid/Use Alternative

  • abemaciclib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    abemaciclib
    1 interaction

    Avoid/Use Alternative

    ritonavir + abemaciclib

    avoid combo: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects; may decr. abemaciclib levels, efficacy (hepatic metabolism altered)

  • acalabrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    acalabrutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + acalabrutinib

    avoid combo: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • acoramidis
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    acoramidis
    1 interaction

    Avoid/Use Alternative

    ritonavir + acoramidis

    avoid combo: combo may decr. acoramidis levels, efficacy (UGT possibly induced)

  • adagrasib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    adagrasib
    1 interaction

    Avoid/Use Alternative

    ritonavir + adagrasib

    avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ado-trastuzumab emtansine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ado-trastuzumab emtansine
    1 interaction

    Avoid/Use Alternative

    ritonavir + ado-trastuzumab emtansine

    avoid combo during ritonavir tx; may start/restart ado-trastuzumab emtansine after ritonavir cleared (approx. 3 inhibitor half-lives): combo may incr. small molecule cytotoxin (DM1) levels, risk of myelosuppression, hepatotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly inhibited)

  • alfentanil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alfentanil
    1 interaction

    Avoid/Use Alternative

    ritonavir + alfentanil

    use alternative or monitor respiratory rate, HR; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • aliskiren
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aliskiren
    1 interaction

    Avoid/Use Alternative

    ritonavir + aliskiren

    avoid combo if ritonavir admin. w/ nirmatrelvir; otherwise, caution advised: combo may incr. aliskiren levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • almotriptan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    almotriptan
    1 interaction

    Avoid/Use Alternative

    ritonavir + almotriptan

    limit almotriptan start dose to 6.25 mg PO x1, max 12.5 mg/24h; avoid combo if concomitant renal or hepatic impairment: combo may incr. almotriptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • alpelisib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alpelisib
    1 interaction

    Avoid/Use Alternative

    ritonavir + alpelisib

    use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

  • apixaban
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    apixaban
    1 interaction

    Avoid/Use Alternative

    ritonavir + apixaban

    ADULT PTS: monitor bleeding s/sx; decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • aprepitant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aprepitant
    1 interaction

    Avoid/Use Alternative

    ritonavir + aprepitant

    avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole bimonthly injection
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aripiprazole bimonthly injection
    1 interaction

    Avoid/Use Alternative

    ritonavir + aripiprazole bimonthly injection

    for concurrent use >14 days, decr. aripiprazole dose to 720 mg q2mo; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole lauroxil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aripiprazole lauroxil
    1 interaction

    Avoid/Use Alternative

    ritonavir + aripiprazole lauroxil

    ARISTADA INITIO: avoid combo; ARISTADA: if concurrent use >14 days, decr. aripiprazole lauroxil 1064 mg q2mo to 441 mg qmo, 882 mg q6wk to 441 mg qmo, 882 mg qmo to 662 mg qmo, 662 mg qmo to 441 mg qmo; if also CYP2D6 PM, decr. 1064 mg q2mo to 441 mg qmo, 882 mg qmo or q6wk to 441 mg qmo, 662 mg qmo to 441 mg qmo; if also combined w/ strong CYP2D6 inhibitor, avoid combo w/ 1064 mg, 882 mg, or 662 mg doses; no dose adjustment if on 441 mg dose: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole monthly injection
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aripiprazole monthly injection
    1 interaction

    Avoid/Use Alternative

    ritonavir + aripiprazole monthly injection

    1-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo; 14-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg or decr. 300 mg dose to 200 mg; if also CYP2D6 PM, decr. IM aripiprazole dose to 200 mg; if also combined w/ strong CYP2D6 inhibitor, decr. IM aripiprazole 400 mg dose to 200 mg and decr. 300 mg dose to 160 mg: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • atidarsagene autotemcel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atidarsagene autotemcel
    1 interaction

    Avoid/Use Alternative

    ritonavir + atidarsagene autotemcel

    avoid combo; D/C ritonavir at least 1mo prior to mobilization: combo may interfere with gene transfer into apheresed cells (antagonistic effects)

  • atrasentan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atrasentan
    1 interaction

    Avoid/Use Alternative

    ritonavir + atrasentan

    avoid combo: combo may incr. atrasentan levels, risk of adverse effects (hepatic transport inhibited)

  • avanafil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    avanafil
    1 interaction

    Avoid/Use Alternative

    ritonavir + avanafil

    avoid combo: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avapritinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    avapritinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + avapritinib

    avoid combo: combo may incr. or decr. avapritinib levels, incr. risk of bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism altered)

  • axitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    axitinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + axitinib

    use alternative or decr. axitinib dose approx. 50%: combo may incr. axitinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • bedaquiline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    ritonavir + bedaquiline

    use alternative or monitor ECG w/ ritonavir tx >2wk; otherwise, monitor ECG: combo may incr. bedaquiline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • bendamustine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bendamustine
    1 interaction

    Avoid/Use Alternative

    ritonavir + bendamustine

    consider alternatives: combo may decr. bendamustine levels, efficacy (hepatic metabolism induced)

  • betamethasone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    betamethasone
    1 interaction

    Avoid/Use Alternative

    ritonavir + betamethasone

    consider alternative (incl. prednisolone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. betamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • betibeglogene autotemcel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    betibeglogene autotemcel
    1 interaction

    Avoid/Use Alternative

    ritonavir + betibeglogene autotemcel

    avoid combo; D/C ritonavir at least 1mo prior to mobilization and until apheresis completed: combo may interfere with gene transfer into apheresed cells (antagonistic effects)

  • bosentan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bosentan
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + bosentan

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Monitor/Modify Tx

    ritonavir + bosentan

    D/C bosentan at least 36h prior to nirmatrelvir/ritonavir tx; otherwise, start bosentan 62.5 mg qd or qod if on stable protease inhibitor tx; if on stable bosentan tx, hold x36h, start protease inhibitor x10 days, then restart bosentan 62.5 mg qd or qod: combo may decr. ritonavir levels, efficacy; may incr. bosentan levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, hepatic transport inhibited)

  • bosutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bosutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + bosutinib

    avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • brigatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    brigatinib
    2 interactions

    Avoid/Use Alternative

    ritonavir + brigatinib

    use alternative or monitor BP, HR; decr. brigatinib dose by approx. 50% as follows: if taking 180 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + brigatinib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • brincidofovir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    brincidofovir
    1 interaction

    Avoid/Use Alternative

    ritonavir + brincidofovir

    consider alternative or monitor LFTs, GI toxicity sx; give brincidofovir at least 3h before ritonavir: combo may incr. brincidofovir levels, risk of hepatotoxicity, GI toxicity, other adverse effects (hepatic transport inhibited)

  • bromocriptine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bromocriptine
    1 interaction

    Avoid/Use Alternative

    ritonavir + bromocriptine

    avoid combo if diabetes tx; otherwise, consider decr. bromocriptine dose: combo may incr. bromocriptine levels, risk of hypotension, other adverse effects; may decr. antidiabetic agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • budesonide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    budesonide
    1 interaction

    Avoid/Use Alternative

    ritonavir + budesonide

    avoid combo; risk may be lower w/ nirmatrelvir/ritonavir tx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • budesonide inhaled
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    budesonide inhaled
    1 interaction

    Avoid/Use Alternative

    ritonavir + budesonide inhaled

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • budesonide nasal
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    budesonide nasal
    1 interaction

    Avoid/Use Alternative

    ritonavir + budesonide nasal

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • budesonide rectal
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    budesonide rectal
    1 interaction

    Avoid/Use Alternative

    ritonavir + budesonide rectal

    avoid combo: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; lower risk with nirmatrelvir/ritonavir tx (hepatic metabolism inhibited)

  • buspirone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    buspirone
    1 interaction

    Avoid/Use Alternative

    ritonavir + buspirone

    consider alternative or restart buspirone dose at 2.5 mg qd: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

  • cabazitaxel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cabazitaxel
    1 interaction

    Avoid/Use Alternative

    ritonavir + cabazitaxel

    use alternative or consider decr. cabazitaxel dose 25%; monitor CBC: combo may incr. cabazitaxel levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • cabotegravir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cabotegravir
    1 interaction

    Avoid/Use Alternative

    ritonavir + cabotegravir

    consider alternative: combo may decr. cabotegravir levels, efficacy (UGT induced)

  • cabozantinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cabozantinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + cabozantinib

    use alternative or monitor ECG, BP, bleeding s/sx; consider cabozantinib dose adjustment: combo may incr. or decr. cabozantinib levels, incr. risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism altered)

  • capivasertib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    capivasertib
    1 interaction

    Avoid/Use Alternative

    ritonavir + capivasertib

    consider alternative: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • cariprazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cariprazine
    1 interaction

    Avoid/Use Alternative

    ritonavir + cariprazine

    IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RITONAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg q: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • cenobamate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cenobamate
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + cenobamate

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + cenobamate

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • ceritinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ceritinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ceritinib

    use alternative or decr. ceritinib dose 33%; monitor ECG, HR, BP, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ciclesonide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ciclesonide
    1 interaction

    Avoid/Use Alternative

    ritonavir + ciclesonide

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. plasma ciclesonide exposure, incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • cladribine oral
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    ritonavir + cladribine oral

    use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated-transport inhibited)

  • clarithromycin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clarithromycin
    1 interaction

    Avoid/Use Alternative

    ritonavir + clarithromycin

    consider alternative for non-MAC infections; otherwise, monitor ECG; if CrCl 30-60: decr. clarithromycin dose 50%; if CrCl <30: decr. clarithromycin dose 75%: combo may incr. clarithromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. clarithromycin active metabolite levels, efficacy (hepatic metabolism inhibited, decr. active metabolite formation)

  • clonidine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clonidine
    1 interaction

    Avoid/Use Alternative

    ritonavir + clonidine

    if ADHD use, avoid combo; otherwise, monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • clopidogrel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clopidogrel
    1 interaction

    Avoid/Use Alternative

    ritonavir + clopidogrel

    avoid combo if ritonavir used in combo w/ darunavir or in combo w/ nirmatrelvir; otherwise, caution advised: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metabolism inhibited, possibly decr. conversion of clopidogrel to active metabolite)

  • cobicistat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cobicistat
    1 interaction

    Avoid/Use Alternative

    ritonavir + cobicistat

    avoid combo; use w/ nirmatrelvir/ritonavir OK: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited; similar effects on CYP3A4)

  • cobimetinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cobimetinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + cobimetinib

    avoid combo: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • codeine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    ritonavir + codeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine, alter active metabolite morphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite morphine)

  • copanlisib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    copanlisib
    1 interaction

    Avoid/Use Alternative

    ritonavir + copanlisib

    use alternative or decr. copanlisib dose to 45 mg; monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • crizotinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + crizotinib

    use alternative or monitor ECG, HR, BP, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dabigatran
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dabigatran
    1 interaction

    Avoid/Use Alternative

    ritonavir + dabigatran

    ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

  • dabrafenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dabrafenib
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + dabrafenib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + dabrafenib

    use alternative: combo may decr. ritonavir levels, efficacy; may incr. dabrafenib levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • daridorexant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    daridorexant
    1 interaction

    Avoid/Use Alternative

    ritonavir + daridorexant

    avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • dasatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dasatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + dasatinib

    use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after ritonavir tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • defactinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    defactinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + defactinib

    avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • deferasirox
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    deferasirox
    1 interaction

    Avoid/Use Alternative

    ritonavir + deferasirox

    use alternative or consider incr. initial deferasirox dose by 50%; monitor serum ferritin levels: combo may decr. deferasirox levels, efficacy (UGT induced)

  • desogestrel (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    desogestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + desogestrel (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • dexamethasone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dexamethasone
    2 interactions

    Avoid/Use Alternative

    ritonavir + dexamethasone

    if multiple myeloma use, use alternative or monitor hypercorticism s/sx; otherwise, consider alternative (incl. prednisolone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may decr. ritonavir levels, efficacy; may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    Caution Advised

    nirmatrelvir + dexamethasone

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • diazoxide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    diazoxide
    1 interaction

    Avoid/Use Alternative

    ritonavir + diazoxide

    avoid combo if also combined w/ strong CYP3A4 inducer; otherwise, monitor glucose: combo may incr. or decr. diazoxide levels, incr. risk of hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • dienogest (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dienogest (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + dienogest (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metabolism induced)

  • dihydrocodeine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    ritonavir + dihydrocodeine

    use alternative or monitor respiratory rate, withdrawal sx; consider dihydrocodeine dose adjustment: combo may incr. dihydrocodeine levels, alter metabolite dihydromorphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite dihydromorphine)

  • disopyramide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    disopyramide
    1 interaction

    Avoid/Use Alternative

    ritonavir + disopyramide

    use alternative or monitor disopyramide levels, HR, ECG: combo may incr. disopyramide levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, neurologic events, other adverse effects (hepatic metabolism inhibited, additive effects)

  • docetaxel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    docetaxel
    1 interaction

    Avoid/Use Alternative

    ritonavir + docetaxel

    use alternative or monitor CBC; consider decr. docetaxel dose 50%: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • dordaviprone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dordaviprone
    1 interaction

    Avoid/Use Alternative

    ritonavir + dordaviprone

    use alternative or monitor ECG, electrolytes; separate admin.; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 375 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • doxorubicin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    doxorubicin
    1 interaction

    Avoid/Use Alternative

    ritonavir + doxorubicin

    avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • drospirenone (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    drospirenone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + drospirenone (contraceptive)

    FOR ALL INDICATIONS: monitor potassium, thrombosis s/sx; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may incr. or decr. drospirenone levels, incr. risk of hyperkalemia, thromboembolism, other adverse effects or decr. contraceptive efficacy (hepatic metabolism altered)

  • duvelisib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    duvelisib
    1 interaction

    Avoid/Use Alternative

    ritonavir + duvelisib

    use alternative or decr. duvelisib dose to 15 mg: combo may incr. duvelisib levels, risk of adverse effects (hepatic metabolism inhibited)

  • efavirenz
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    efavirenz
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + efavirenz

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    Monitor/Modify Tx

    ritonavir + efavirenz

    monitor LFTs if ritonavir at least 1000 mg/day; otherwise, monitor ECG: combo may decr. ritonavir levels, efficacy; may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, elevated LFTs, paresthesia, CNS and other adverse effects (hepatic metabolism altered, P-gp-mediated transport induced, mechanism unknown)

  • elacestrant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elacestrant
    1 interaction

    Avoid/Use Alternative

    ritonavir + elacestrant

    avoid combo: combo may incr. or decr. elacestrant levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • elbasvir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elbasvir
    1 interaction

    Avoid/Use Alternative

    ritonavir + elbasvir

    avoid combo: combo may incr. elbasvir levels, risk of adverse effects (hepatic metabolism inhibited)

  • elinzanetant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elinzanetant
    1 interaction

    Avoid/Use Alternative

    ritonavir + elinzanetant

    avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • elivaldogene autotemcel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elivaldogene autotemcel
    1 interaction

    Avoid/Use Alternative

    ritonavir + elivaldogene autotemcel

    avoid combo; D/C ritonavir at least 1mo prior to mobilization and until apheresis completed: combo may interfere with gene transfer into apheresed cells (antagonistic effects)

  • elvitegravir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elvitegravir
    1 interaction

    Avoid/Use Alternative

    ritonavir + elvitegravir

    avoid combo: combo may incr. elvitegravir levels, risk of adverse effects (hepatic metabolism inhibited, duplicate therapy)

  • ensartinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited, P-gp-mediated transport possibly inhibited, additive effects)

  • entrectinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    entrectinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + entrectinib

    PEDS PTS w/ ENTRECTINIB START DOSE <200 mg/day: avoid combo; ADULT AND PEDS PTS >2yo: consider alternative: combo may incr. or decr. entrectinib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • erdafitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    erdafitinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + erdafitinib

    use alternative or monitor phosphate levels: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • erlotinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    erlotinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + erlotinib

    use alternative or consider decr. erlotinib dose by 50 mg/day decrements: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • estazolam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    estazolam
    1 interaction

    Avoid/Use Alternative

    ritonavir + estazolam

    use alternative or monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • estradiol (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + estradiol (contraceptive)

    FOR ALL INDICATIONS: monitor thrombosis s/sx; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. estradiol levels, contraceptive efficacy; may initially incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced, UGT induced; hepatic metabolism inhibited)

  • ethinyl estradiol (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + ethinyl estradiol (contraceptive)

    FOR ALL INDICATIONS: monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced, UGT induced; hepatic metabolism inhibited)

  • ethynodiol (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ethynodiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + ethynodiol (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metabolism induced)

  • etonogestrel (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etonogestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + etonogestrel (contraceptive)

    FOR ALL INDICATIONS: monitor thrombosis s/sx; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may incr. or decr. etonogestrel levels, incr. risk of thromboembolism, other adverse effects or decr. contraceptive efficacy (hepatic metabolism altered)

  • etoposide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etoposide
    1 interaction

    Avoid/Use Alternative

    ritonavir + etoposide

    use alternative or monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • etrasimod
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etrasimod
    1 interaction

    Avoid/Use Alternative

    ritonavir + etrasimod

    if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • etravirine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etravirine
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + etravirine

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + etravirine

    avoid combo w/ ritonavir 600 mg bid; OK when used in low-dose to boost certain other protease inhibitors: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

  • everolimus
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    everolimus
    1 interaction

    Avoid/Use Alternative

    ritonavir + everolimus

    TRANSPLANT: use alternative or monitor everolimus levels, CBC; ALL OTHER INDICATIONS: avoid combo: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • fedratinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fedratinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + fedratinib

    consider alternative: combo may incr. or decr. fedratinib levels, incr. risk of myelosuppression, hepatotoxicity, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • fentanyl
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fentanyl
    1 interaction

    Avoid/Use Alternative

    ritonavir + fentanyl

    use alternative or monitor respiratory rate, HR; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fesoterodine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fesoterodine
    1 interaction

    Avoid/Use Alternative

    ritonavir + fesoterodine

    avoid combo in peds pts <35 kg; adjust max fesoterodine dose to 4 mg/day in adults and peds pts >35 kg: combo may incr. fesoterodine active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • fexinidazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fexinidazole
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + fexinidazole

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + fexinidazole

    use alternative: combo may decr. ritonavir levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

  • fingolimod
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fingolimod
    1 interaction

    Avoid/Use Alternative

    ritonavir + fingolimod

    use alternative or monitor HR, ECG overnight, esp. during fingolimod initiation/titration: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • fluticasone propionate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fluticasone propionate
    1 interaction

    Avoid/Use Alternative

    ritonavir + fluticasone propionate

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

  • fosaprepitant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fosaprepitant
    1 interaction

    Avoid/Use Alternative

    ritonavir + fosaprepitant

    avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

  • futibatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    futibatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + futibatinib

    avoid combo: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • gepotidacin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    gepotidacin
    1 interaction

    Avoid/Use Alternative

    ritonavir + gepotidacin

    use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • gilteritinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    gilteritinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + gilteritinib

    consider alternative or monitor ECG: combo may incr. or decr. gilteritinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • glasdegib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glasdegib
    1 interaction

    Avoid/Use Alternative

    ritonavir + glasdegib

    consider alternative or monitor CBC, ECG: combo may incr. or decr. glasdegib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • glecaprevir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glecaprevir
    1 interaction

    Avoid/Use Alternative

    ritonavir + glecaprevir

    avoid combo: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • hydrocodone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    ritonavir + hydrocodone

    use alternative or monitor respiratory rate, ECG; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ibrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ibrutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ibrutinib

    avoid combo: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • idelalisib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    idelalisib
    1 interaction

    Avoid/Use Alternative

    ritonavir + idelalisib

    use alternative or monitor LFTs, CBC, GI toxicity sx: combo may incr. idelalisib levels, risk of hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (hepatic metabolism inhibited)

  • imlunestrant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    imlunestrant
    1 interaction

    Avoid/Use Alternative

    ritonavir + imlunestrant

    use alternative or decr. imlunestrant dose to 200 mg once daily: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

  • irinotecan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    irinotecan
    1 interaction

    Avoid/Use Alternative

    ritonavir + irinotecan

    use alternative or D/C ritonavir >1wk prior to irinotecan start: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited, BCRP-mediated transport inhibited)

  • ivacaftor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ivacaftor
    1 interaction

    Avoid/Use Alternative

    ritonavir + ivacaftor

    pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg 2x/wk; 6 mo-5 yo and 7-13.9 kg: give 50 mg 2x/wk; 6 mo-5 yo and >14 kg: give 75 mg 2x/wk; 6 yo and older: give 150 mg 2x/wk: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • ixabepilone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ixabepilone
    1 interaction

    Avoid/Use Alternative

    ritonavir + ixabepilone

    use alternative or monitor CBC; consider decr. ixabepilone dose to 20 mg/m^2, wait 1wk after inhibitor D/C before incr. dose: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

  • landiolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    landiolol
    1 interaction

    Avoid/Use Alternative

    ritonavir + landiolol

    use alternative or monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lapatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lapatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + lapatinib

    use alternative or monitor ECG; consider decr. lapatinib dose to 500 mg/day: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • larotrectinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    larotrectinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + larotrectinib

    use alternative or decr. larotrectinib dose 50%: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • lefamulin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    ritonavir + lefamulin

    ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • lemborexant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lemborexant
    1 interaction

    Avoid/Use Alternative

    ritonavir + lemborexant

    avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • leniolisib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    leniolisib
    1 interaction

    Avoid/Use Alternative

    ritonavir + leniolisib

    avoid combo: combo may incr. leniolisib levels, risk of adverse effects (hepatic metabolism inhibited)

  • letermovir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    letermovir
    1 interaction

    Avoid/Use Alternative

    ritonavir + letermovir

    avoid combo: combo may decr. letermovir levels, efficacy (hepatic metabolism induced, UGT induced)

  • levoketoconazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levoketoconazole
    1 interaction

    Avoid/Use Alternative

    ritonavir + levoketoconazole

    avoid combo x2wk before and during levoketoconazole tx: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • levonorgestrel (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levonorgestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + levonorgestrel (contraceptive)

    FOR ALL INDICATIONS: monitor thrombosis s/sx; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may incr. or decr. levonorgestrel levels, incr. risk of thromboembolism, other adverse effects or decr. contraceptive efficacy (hepatic metabolism altered)

  • levonorgestrel (post-coital contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levonorgestrel (post-coital contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + levonorgestrel (post-coital contraceptive)

    consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metabolism induced)

  • lofexidine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lofexidine
    1 interaction

    Avoid/Use Alternative

    ritonavir + lofexidine

    use alternative or monitor HR: combo may incr. risk of bradycardia (additive effects)

  • lopinavir/ritonavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lopinavir/ ritonavir
    2 interactions

    Avoid/Use Alternative

    ritonavir + lopinavir/ ritonavir

    avoid additional ritonavir; use w/ nirmatrelvir/ritonavir OK: combo may incr. lopinavir levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    nirmatrelvir + lopinavir/ ritonavir

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • lorlatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lorlatinib
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + lorlatinib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + lorlatinib

    use alternative: combo may decr. levels of both drugs, efficacy; may incr. lorlatinib levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism induced, P-gp-mediated transport induced; hepatic metabolism inhibited, additive effects)

  • lovotibeglogene autotemcel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lovotibeglogene autotemcel
    1 interaction

    Avoid/Use Alternative

    ritonavir + lovotibeglogene autotemcel

    avoid combo; D/C ritonavir at least 1mo prior to mobilization and until all apheresis cycles completed: combo may interfere with gene transfer into apheresed cells (antagonistic effects)

  • lurbinectedin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lurbinectedin
    1 interaction

    Avoid/Use Alternative

    ritonavir + lurbinectedin

    use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • macitentan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    macitentan
    1 interaction

    Avoid/Use Alternative

    ritonavir + macitentan

    use alternative pulmonary HTN tx: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

  • mavacamten
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mavacamten
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + mavacamten

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + mavacamten

    consider alternative or monitor cardiac function, including LVEF; if patient stable on ritonavir, initiate mavacamten at 2.5 mg qd; if adding short-term (<1wk) ritonavir tx to existing mavacamten, hold mavacamten until ritonavir D/C; if adding longer-term (>1wk) ritonavir tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start ritonavir tx if on mavacamten 2.5 mg qd: combo may incr. or decr. mavacamten levels, incr. risk of heart failure, other adverse effects or decr. efficacy; may decr. ritonavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

  • medroxyprogesterone (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    medroxyprogesterone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + medroxyprogesterone (contraceptive)

    use additional non-hormonal or alternative contraception: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metabolism induced)

  • mefloquine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mefloquine
    1 interaction

    Avoid/Use Alternative

    ritonavir + mefloquine

    consider alternative or monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. ritonavir levels, efficacy (additive effects; mechanism unknown)

  • meperidine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    ritonavir + meperidine

    use alternative or monitor withdrawal sx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity (hepatic metabolism induced, incr. toxic metabolite formation)

  • methylprednisolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    methylprednisolone
    1 interaction

    Avoid/Use Alternative

    ritonavir + methylprednisolone

    consider alternative or decr. methylprednisolone dose, especially if long-term use; alternatives incl. prednisolone; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • midostaurin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    midostaurin
    1 interaction

    Avoid/Use Alternative

    ritonavir + midostaurin

    consider alternative or monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • mifepristone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mifepristone
    1 interaction

    Avoid/Use Alternative

    ritonavir + mifepristone

    use alternative or decr. mifepristone dose as follows: if on mifepristone 1200 mg, decr. dose to 900 mg; if on mifepristone 900 mg, decr. dose to 600 mg, may titrate to max 900 mg/day; if on mifepristone 600 mg, decr. dose to 300 mg, may titrate to max 600 mg/day; if on mifepristone 300 mg, no dose adjustment needed; caution advised if pregnancy termination use: combo may incr. mifepristone levels, risk of adverse effects (hepatic metabolism inhibited)

  • mitapivat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mitapivat
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + mitapivat

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + mitapivat

    avoid combo: combo may incr. or decr. mitapivat levels, incr. risk of adverse effects or decr. efficacy; may decr. ritonavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

  • mobocertinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mobocertinib
    2 interactions

    Avoid/Use Alternative

    ritonavir + mobocertinib

    avoid combo: combo may incr. or decr. mobocertinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy; may decr. ritonavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + mobocertinib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • modafinil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    modafinil
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + modafinil

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + modafinil

    use alternative: combo may decr. ritonavir levels, efficacy; may incr. modafinil levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • mometasone inhaled
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mometasone inhaled
    1 interaction

    Avoid/Use Alternative

    ritonavir + mometasone inhaled

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. mometasone levels, risk of systemic corticosteroid effects including Cushing syndrome, adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • mometasone nasal
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mometasone nasal
    1 interaction

    Avoid/Use Alternative

    ritonavir + mometasone nasal

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. mometasone levels, risk of systemic corticosteroid effects including Cushing syndrome, adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • neratinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + neratinib

    avoid combo: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • nilotinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nilotinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + nilotinib

    use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • nimodipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nimodipine
    1 interaction

    Avoid/Use Alternative

    ritonavir + nimodipine

    use alternative or monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nirogacestat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nirogacestat
    1 interaction

    Avoid/Use Alternative

    ritonavir + nirogacestat

    avoid combo: combo may incr. or decr. nirogacestat levels, incr. risk of hypophosphatemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • nisoldipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nisoldipine
    1 interaction

    Avoid/Use Alternative

    ritonavir + nisoldipine

    use alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • norelgestromin (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    norelgestromin (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + norelgestromin (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metabolism induced)

  • norethindrone (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    norethindrone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + norethindrone (contraceptive)

    FOR ALL INDICATIONS: monitor thrombosis s/sx; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may incr. or decr. norethindrone levels, incr. risk of thromboembolism, other adverse effects or decr. contraceptive efficacy (hepatic metabolism altered)

  • norgestimate (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    norgestimate (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + norgestimate (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

  • norgestrel (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    norgestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + norgestrel (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • olaparib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    olaparib
    1 interaction

    Avoid/Use Alternative

    ritonavir + olaparib

    use alternative or monitor CBC; decr. olaparib dose to 100 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • oliceridine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    oliceridine
    1 interaction

    Avoid/Use Alternative

    ritonavir + oliceridine

    use alternative or monitor respiratory rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • omaveloxolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    omaveloxolone
    2 interactions

    Avoid/Use Alternative

    ritonavir + omaveloxolone

    use alternative or decr. omaveloxolone dose to 50 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + omaveloxolone

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • orlistat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    orlistat
    1 interaction

    Avoid/Use Alternative

    ritonavir + orlistat

    consider alternative: combo may decr. ritonavir levels, efficacy (absorption possibly decreased)

  • oxycodone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    ritonavir + oxycodone

    use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ozanimod
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ozanimod
    1 interaction

    Avoid/Use Alternative

    ritonavir + ozanimod

    use alternative or monitor HR, ECG, especially when starting or restarting ozanimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • palbociclib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    palbociclib
    1 interaction

    Avoid/Use Alternative

    ritonavir + palbociclib

    use alternative or decr. palbociclib dose to 75 mg qd: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • palovarotene
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    palovarotene
    1 interaction

    Avoid/Use Alternative

    ritonavir + palovarotene

    avoid combo: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • pazopanib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pazopanib
    1 interaction

    Avoid/Use Alternative

    ritonavir + pazopanib

    avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • pemigatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pemigatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + pemigatinib

    use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • pexidartinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pexidartinib
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + pexidartinib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + pexidartinib

    use alternative or monitor LFTs, decr. pexidartinib dose as follows: if on pexidartinib 500 mg/day or 375 mg/day, decr. to 125 mg bid; if on pexidartinib 250 mg/day, decr. to 125 mg qd: combo may decr. ritonavir levels, efficacy; may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • pibrentasvir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pibrentasvir
    1 interaction

    Avoid/Use Alternative

    ritonavir + pibrentasvir

    avoid combo: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • pirtobrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pirtobrutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + pirtobrutinib

    consider alternative: combo may incr. or decr. pirtobrutinib levels, incr. risk of serious infection, myelosuppression, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • ponatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ponatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ponatinib

    monitor CBC; if on ponatinib 45 mg/day, decr. to ponatinib 30 mg/day; if on ponatinib 30 mg/day, decr. to ponatinib 15 mg/day; if on ponatinib 15 mg/day, decr. to ponatinib 10 mg/day; if on ponatinib 10 mg/day, avoid ritonavir: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ponesimod
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ponesimod
    1 interaction

    Avoid/Use Alternative

    ritonavir + ponesimod

    use alternative or monitor HR, ECG, especially when starting or restarting ponesimod tx: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • posaconazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    posaconazole
    1 interaction

    Avoid/Use Alternative

    ritonavir + posaconazole

    use alternative or monitor for breakthrough fungal infection: combo may incr. ritonavir levels, risk of adverse effects; may decr. posaconazole levels, efficacy (hepatic metabolism inhibited; UGT possibly induced)

  • pralsetinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + pralsetinib

    use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd or 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • prednisone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    prednisone
    2 interactions

    Avoid/Use Alternative

    ritonavir + prednisone

    consider alternative (incl. prednisolone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. prednisone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + prednisone

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • quetiapine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    quetiapine
    1 interaction

    Avoid/Use Alternative

    ritonavir + quetiapine

    consider alternative or decr. quetiapine to 1/6th of original dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • quinine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    quinine
    1 interaction

    Avoid/Use Alternative

    ritonavir + quinine

    avoid combo: combo may incr. quinine levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quizartinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + quizartinib

    monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • red yeast rice
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    red yeast rice
    1 interaction

    Avoid/Use Alternative

    ritonavir + red yeast rice

    use alternative or monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, hepatic transport inhibited, P-gp-mediated transport inhibited, red yeast rice contains varying amounts of lovastatin)

  • regorafenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    regorafenib
    1 interaction

    Avoid/Use Alternative

    ritonavir + regorafenib

    avoid combo: combo may incr. regorafenib levels, risk of adverse effects (hepatic metabolism inhibited)

  • relugolix
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    ritonavir + relugolix

    PROSTATE CANCER: may hold relugolix if ritonavir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ritonavir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ritonavir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

  • remibrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    remibrutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + remibrutinib

    avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • repotrectinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    repotrectinib
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + repotrectinib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + repotrectinib

    avoid combo; D/C ritonavir 3-5 half-lives prior to repotrectinib tx: combo may decr. ritonavir levels, efficacy; may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism induced; P-gp-mediated transport inhibited, hepatic metabolism altered)

  • retapamulin topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    retapamulin topical
    1 interaction

    Avoid/Use Alternative

    ritonavir + retapamulin topical

    avoid combo in pts <24 mo; otherwise, caution advised: combo may incr. retapamulin levels, risk of adverse effects (hepatic metabolism inhibited)

  • ribociclib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ribociclib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ribociclib

    use alternative or monitor ECG, electrolytes, CBC; decr. ribociclib dose as follows: EARLY BREAST CA: decr. ribociclib dose to 200 mg qd; ADVANCED OR METASTATIC BREAST CA: decr. ribociclib dose to 400 mg qd: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • rifabutin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rifabutin
    2 interactions

    Avoid/Use Alternative

    ritonavir + rifabutin

    avoid use when rifabutin is given as part of a fixed-dose combo for H. pylori; otherwise, decr. rifabutin dose to 150 mg/day; monitor CBC, uveitis s/sx; consider monitoring rifabutin levels: combo may decr. ritonavir levels, efficacy; may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects (hepatic metabolism induced, P-gp-mediated transport possibly induced; hepatic metabolism inhibited)

    Caution Advised

    nirmatrelvir + rifabutin

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • rilzabrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rilzabrutinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + rilzabrutinib

    avoid combo if ritonavir use greater than 7 days; use alternative or hold rilzabrutinib if ritonavir use less than 7 days: combo may incr. rilzabrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • rimegepant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rimegepant
    1 interaction

    Avoid/Use Alternative

    ritonavir + rimegepant

    avoid combo: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • rivaroxaban
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    ritonavir + rivaroxaban

    avoid combo: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • roflumilast
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    roflumilast
    1 interaction

    Avoid/Use Alternative

    ritonavir + roflumilast

    consider alternative: combo may incr. or decr. roflumilast levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • ruxolitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ruxolitinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + ruxolitinib

    monitor CBC; ACUTE OR CHRONIC GVHD: no adjustment; MYELOFIBROSIS INITIATION: decr. ruxolitinib start dose to 10 mg bid if Plt >100,000 or 5 mg qd if Plt 50,000-100,000; POLYCYTHEMIA VERA INITIATION: decr. ruxolitinib start dose to 5 mg bid; MYELOFIBROSIS AND POLYCYTHEMIA VERA ONGOING TX: decr. ruxolitinib maint. dose by 50%; avoid combo if maint. dose is 5 mg/day: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ruxolitinib topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ruxolitinib topical
    1 interaction

    Avoid/Use Alternative

    ritonavir + ruxolitinib topical

    avoid combo: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • sacituzumab govitecan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sacituzumab govitecan
    1 interaction

    Avoid/Use Alternative

    ritonavir + sacituzumab govitecan

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • salmeterol inhaled
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    salmeterol inhaled
    1 interaction

    Avoid/Use Alternative

    ritonavir + salmeterol inhaled

    avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

  • sebetralstat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sebetralstat
    1 interaction

    Avoid/Use Alternative

    ritonavir + sebetralstat

    avoid combo: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • segesterone (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    segesterone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + segesterone (contraceptive)

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metabolism induced)

  • selpercatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    selpercatinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + selpercatinib

    use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 40 mg bid; if on selpercatinib 160 mg bid, decr. to 80 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • selumetinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    selumetinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + selumetinib

    consider alternative: combo may incr. or decr. selumetinib levels, incr. risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • sevabertinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sevabertinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + sevabertinib

    use alternative or decr. sevabertinib dose as follows: if on sevabertinib 20 mg bid, decr. to 10 mg bid; if on sevabertinib 10 mg bid, decr. to 10 mg qd; if on sevabertinib 10 mg qd, hold sevabertinib until ritonavir D/C: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • siponimod
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    siponimod
    1 interaction

    Avoid/Use Alternative

    ritonavir + siponimod

    consider alternative or monitor HR, ECG, especially when starting or restarting siponimod tx; if also combined w/ strong CYP2C9 inhibitor, avoid combo: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sirolimus
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sirolimus
    1 interaction

    Avoid/Use Alternative

    ritonavir + sirolimus

    use alternative or monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • sirolimus albumin-bound
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    ritonavir + sirolimus albumin-bound

    avoid combo: combo may incr. or decr. sirolimus albumin-bound levels, incr. risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism altered, P-gp-mediated transport inhibited)

  • sonidegib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sonidegib
    1 interaction

    Avoid/Use Alternative

    ritonavir + sonidegib

    avoid combo: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

  • sotorasib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sotorasib
    2 interactions

    Avoid/Use Alternative

    nirmatrelvir + sotorasib

    avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + sotorasib

    use alternative: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • sparsentan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sparsentan
    1 interaction

    Avoid/Use Alternative

    ritonavir + sparsentan

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • sufentanil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sufentanil
    1 interaction

    Avoid/Use Alternative

    ritonavir + sufentanil

    use alternative or monitor respiratory rate, HR; consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sunitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sunitinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + sunitinib

    use alternative or monitor ECG, electrolytes; consider decr. sunitinib to minimum dose as follows: GIST or RCC: 37.5 mg/day, 4wk on, 2wk off; PNET: 25 mg/day: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • sunvozertinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sunvozertinib
    2 interactions

    Avoid/Use Alternative

    ritonavir + sunvozertinib

    use alternative or decr. sunvozertinib dose to 150 mg once daily: combo may incr. sunvozertinib levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + sunvozertinib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • suvorexant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    suvorexant
    1 interaction

    Avoid/Use Alternative

    ritonavir + suvorexant

    avoid combo: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • tadalafil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tadalafil
    1 interaction

    Avoid/Use Alternative

    ritonavir + tadalafil

    BENIGN PROSTATIC HYPERPLASIA: avoid combo; PULMONARY HTN: avoid combo if ritonavir use w/ nirmatrelvir; otherwise monitor BP, start tadalafil 20 mg qd if on ritonavir >1wk; if on tadalafil, hold x24h before and x1wk after ritonavir start, then resume tadalafil 20 mg qd, max 40 mg qd; ERECTILE DYSFUNCTION: monitor BP; max tadalafil dose 10 mg q72h if prn use, 2.5 mg qd if daily use: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • taletrectinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    taletrectinib
    1 interaction

    Avoid/Use Alternative

    ritonavir + taletrectinib

    avoid combo: combo may incr. or decr. taletrectinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • tamsulosin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tamsulosin
    1 interaction

    Avoid/Use Alternative

    ritonavir + tamsulosin

    avoid combo: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • tazemetostat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tazemetostat
    2 interactions

    Avoid/Use Alternative

    ritonavir + tazemetostat

    use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + tazemetostat

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • temsirolimus
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    temsirolimus
    1 interaction

    Avoid/Use Alternative

    ritonavir + temsirolimus

    use alternative or monitor CBC; consider decr. temsirolimus dose to 12.5 mg/wk: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • thiotepa
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    thiotepa
    1 interaction

    Avoid/Use Alternative

    ritonavir + thiotepa

    use alternative or monitor CBC: combo may incr. thiotepa levels, risk of serious infection, myelosuppression, other adverse effects; may decr. thiotepa active metabolite levels, efficacy (hepatic metabolism inhibited, decr. metabolite formation)

  • ticagrelor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ticagrelor
    1 interaction

    Avoid/Use Alternative

    ritonavir + ticagrelor

    avoid combo: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • topotecan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    topotecan
    1 interaction

    Avoid/Use Alternative

    ritonavir + topotecan

    avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

  • toremifene
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    ritonavir + toremifene

    use alternative or monitor ECG: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • trabectedin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    trabectedin
    1 interaction

    Avoid/Use Alternative

    ritonavir + trabectedin

    avoid combo: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • tramadol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    ritonavir + tramadol

    use alternative or monitor respiratory rate, ECG, consider decr. tramadol dose: combo may incr. tramadol, alter active metabolite levels, incr. risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite)

  • trazodone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    trazodone
    1 interaction

    Avoid/Use Alternative

    ritonavir + trazodone

    use alternative or monitor ECG, BP; consider decr. trazodone dose: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • tretinoin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tretinoin
    1 interaction

    Avoid/Use Alternative

    ritonavir + tretinoin

    use alternative: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

  • triamcinolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    triamcinolone
    1 interaction

    Avoid/Use Alternative

    ritonavir + triamcinolone

    consider alternative (incl. prednisolone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. triamcinolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • ulipristal (post-coital contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ulipristal (post-coital contraceptive)
    1 interaction

    Avoid/Use Alternative

    ritonavir + ulipristal (post-coital contraceptive)

    avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metabolism induced)

  • vardenafil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vardenafil
    1 interaction

    Avoid/Use Alternative

    ritonavir + vardenafil

    max vardenafil dose 2.5 mg/72h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • vemurafenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vemurafenib
    2 interactions

    Avoid/Use Alternative

    ritonavir + vemurafenib

    use alternative or monitor ECG; consider decr. vemurafenib dose: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + vemurafenib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • vinblastine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vinblastine
    2 interactions

    Avoid/Use Alternative

    ritonavir + vinblastine

    consider alternative or hold ritonavir if hematologic or GI toxicity: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + vinblastine

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • vincristine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vincristine
    1 interaction

    Avoid/Use Alternative

    ritonavir + vincristine

    consider alternative or hold ritonavir if hematologic or GI toxicity: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vinorelbine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vinorelbine
    1 interaction

    Avoid/Use Alternative

    ritonavir + vinorelbine

    consider alternative or hold ritonavir if hematologic or GI toxicity: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vorapaxar
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vorapaxar
    1 interaction

    Avoid/Use Alternative

    ritonavir + vorapaxar

    avoid combo: combo may incr. vorapaxar levels, risk of adverse effects (hepatic metabolism inhibited)

  • vorasidenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vorasidenib
    2 interactions

    Avoid/Use Alternative

    ritonavir + vorasidenib

    avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + vorasidenib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

  • zavegepant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zavegepant
    1 interaction

    Avoid/Use Alternative

    ritonavir + zavegepant

    avoid combo: combo may incr. zavegepant levels, risk of adverse effects (hepatic transport inhibited)

  • zidovudine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zidovudine
    1 interaction

    Avoid/Use Alternative

    ritonavir + zidovudine

    consider alternative: combo may decr. zidovudine levels, efficacy (UGT induced)

Monitor/Modify Tx

  • acarbose
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    acarbose
    1 interaction

    Monitor/Modify Tx

    ritonavir + acarbose

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • acebutolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + acebutolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • adenosine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    adenosine
    1 interaction

    Monitor/Modify Tx

    ritonavir + adenosine

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • afatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    ritonavir + afatinib

    decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • aficamten
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aficamten
    1 interaction

    Monitor/Modify Tx

    ritonavir + aficamten

    monitor cardiac fxn, incl. LVEF: combo may incr. aficamten levels, risk of cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

  • alectinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alectinib
    1 interaction

    Monitor/Modify Tx

    ritonavir + alectinib

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • allopurinol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    ritonavir + allopurinol

    monitor uric acid levels: combo may decr. allopurinol efficacy (antagonistic effects)

  • alogliptin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alogliptin
    1 interaction

    Monitor/Modify Tx

    ritonavir + alogliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • alprazolam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alprazolam
    1 interaction

    Monitor/Modify Tx

    ritonavir + alprazolam

    monitor respiratory rate; if on stable alprazolam tx and initiating ritonavir or starting both drugs together, decr. alprazolam dose 50%, may incr. alprazolam to target dose after 10-14 days; if on stable ritonavir and initiating alprazolam, no alprazolam dosage adjustment necessary: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • aminophylline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    ritonavir + aminophylline

    monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metabolism induced, aminophylline converted to theophylline)

  • amitriptyline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    ritonavir + amitriptyline

    monitor amitriptyline levels, ECG: combo may incr. amitriptyline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • amlodipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    ritonavir + amlodipine

    monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)

  • amphetamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    ritonavir + amphetamine

    monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. amphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism possibly inhibited)

  • apraclonidine ophthalmic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    apraclonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    ritonavir + apraclonidine ophthalmic

    monitor HR if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of bradycardia (additive effects)

  • aripiprazole oral
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    ritonavir + aripiprazole oral

    decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • arsenic trioxide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    arsenic trioxide
    1 interaction

    Monitor/Modify Tx

    ritonavir + arsenic trioxide

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • artemether/lumefantrine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    artemether/ lumefantrine
    2 interactions

    Monitor/Modify Tx

    ritonavir + artemether/ lumefantrine

    monitor ECG: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + artemether/ lumefantrine

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • articaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    articaine
    1 interaction

    Monitor/Modify Tx

    ritonavir + articaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • asciminib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    ritonavir + asciminib

    if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • atazanavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atazanavir
    1 interaction

    Monitor/Modify Tx

    ritonavir + atazanavir

    see atazanavir Adult/Peds Dosing for specific combo doses used for therapeutic advantage; monitor HR, ECG: ritonavir boosts atazanavir levels, efficacy; combo may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metabolism inhibited; additive effects)

  • atenolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + atenolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • atogepant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    ritonavir + atogepant

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • atorvastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    ritonavir + atorvastatin

    use lowest effective atorvastatin dose; monitor CK, myopathy sx; consider holding atorvastatin if ritonavir admin. w/ nirmatrelvir: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • atovaquone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    atovaquone
    1 interaction

    Monitor/Modify Tx

    ritonavir + atovaquone

    consider incr. atovaquone dose if atovaquone also combined w/ proguanil; no dose adjustment needed if using atovaquone oral suspension: combo may decr. atovaquone levels, efficacy (mechanism unknown)

  • avacopan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    avacopan
    1 interaction

    Monitor/Modify Tx

    ritonavir + avacopan

    decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

  • avatrombopag
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    avatrombopag
    1 interaction

    Monitor/Modify Tx

    ritonavir + avatrombopag

    CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • betaxolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + betaxolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • betaxolol ophthalmic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    betaxolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    ritonavir + betaxolol ophthalmic

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • bexagliflozin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bexagliflozin
    1 interaction

    Monitor/Modify Tx

    ritonavir + bexagliflozin

    monitor glucose: combo may decr. bexagliflozin levels, antidiabetic agent efficacy (UGT induced, antagonistic effects)

  • bisoprolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + bisoprolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • bortezomib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    ritonavir + bortezomib

    monitor CBC; consider decr. bortezomib dose: combo may incr. bortezomib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • brentuximab vedotin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    brentuximab vedotin
    1 interaction

    Monitor/Modify Tx

    ritonavir + brentuximab vedotin

    monitor CBC, LFTs: combo may incr. brentuximab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • brexpiprazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    ritonavir + brexpiprazole

    decr. brexpiprazole dose 50%; if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • bupivacaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bupivacaine
    1 interaction

    Monitor/Modify Tx

    ritonavir + bupivacaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • bupivacaine liposomal
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bupivacaine liposomal
    1 interaction

    Monitor/Modify Tx

    ritonavir + bupivacaine liposomal

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • buprenorphine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    ritonavir + buprenorphine

    monitor respiratory rate, ECG; consider decr. buprenorphine dose: combo may incr. buprenorphine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • butorphanol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    ritonavir + butorphanol

    monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • caffeine citrate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    ritonavir + caffeine citrate

    monitor caffeine levels: combo may decr. caffeine levels, efficacy (hepatic metabolism induced)

  • canagliflozin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    canagliflozin
    1 interaction

    Monitor/Modify Tx

    ritonavir + canagliflozin

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced, antagonistic effects)

  • carteolol ophthalmic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    carteolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    ritonavir + carteolol ophthalmic

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • carvedilol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    ritonavir + carvedilol

    monitor BP, HR; consider monitoring ECG: combo may incr. carvedilol levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • chloroprocaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    chloroprocaine
    1 interaction

    Monitor/Modify Tx

    ritonavir + chloroprocaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • cilostazol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    ritonavir + cilostazol

    decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metabolism inhibited)

  • cinacalcet
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cinacalcet
    1 interaction

    Monitor/Modify Tx

    ritonavir + cinacalcet

    monitor iPTH, calcium, ECG: combo may incr. cinacalcet levels, risk of severe hypocalcemia (including life-threatening), QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited)

  • clonazepam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clonazepam
    1 interaction

    Monitor/Modify Tx

    ritonavir + clonazepam

    monitor respiratory rate; consider decr. clonazepam dose: combo may incr. clonazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clorazepate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clorazepate
    1 interaction

    Monitor/Modify Tx

    ritonavir + clorazepate

    monitor respiratory rate; consider decr. clorazepate dose: combo may incr. clorazepate levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clozapine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    ritonavir + clozapine

    monitor ECG, BP, HR; consider clozapine dose adjustment: combo may incr. or decr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, severe bradycardia, other adverse effects or decr. efficacy (hepatic metabolism altered, additive effects)

  • colesevelam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    colesevelam
    1 interaction

    Monitor/Modify Tx

    ritonavir + colesevelam

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • cyclophosphamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    ritonavir + cyclophosphamide

    monitor CBC, renal, cardiac fxn: combo may incr. or decr. cyclophosphamide active metabolite levels, incr. risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects or decr. efficacy (hepatic metabolism possibly altered, incr. cytotoxic metabolite formation)

  • cyclosporine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    ritonavir + cyclosporine

    monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • dapagliflozin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dapagliflozin
    1 interaction

    Monitor/Modify Tx

    ritonavir + dapagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • darifenacin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    darifenacin
    1 interaction

    Monitor/Modify Tx

    ritonavir + darifenacin

    adjust max darifenacin dose to 7.5 mg/day: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

  • darunavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    darunavir
    1 interaction

    Monitor/Modify Tx

    ritonavir + darunavir

    see darunavir Adult/Peds Dosing for specific combo doses used for therapeutic advantage: combo incr. darunavir levels, efficacy when boosted with ritonavir (hepatic metabolism inhibited)

  • deflazacort
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    ritonavir + deflazacort

    decr. deflazacort to 1/3 usual dose; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • desipramine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    ritonavir + desipramine

    monitor desipramine levels, ECG; consider decr. desipramine dose: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dexmedetomidine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    ritonavir + dexmedetomidine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • dexmedetomidine injection
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    ritonavir + dexmedetomidine injection

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • dextroamphetamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    ritonavir + dextroamphetamine

    monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism possibly inhibited)

  • diazepam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    ritonavir + diazepam

    monitor respiratory rate; consider decr. diazepam dose: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • digoxin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    ritonavir + digoxin

    monitor digoxin levels, HR, ECG; decr. digoxin frequency or dose by 30-50%: combo may incr. digoxin levels, risk of PR interval prolongation, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • diltiazem
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    ritonavir + diltiazem

    monitor BP, HR, consider monitoring ECG; consider decr. diltiazem dose: combo may incr. diltiazem levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dofetilide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    ritonavir + dofetilide

    monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • donepezil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    donepezil
    1 interaction

    Monitor/Modify Tx

    ritonavir + donepezil

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • doxercalciferol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    doxercalciferol
    1 interaction

    Monitor/Modify Tx

    ritonavir + doxercalciferol

    monitor efficacy: combo may decr. doxercalciferol efficacy (hepatic metabolism inhibited, decr. conversion to activated vitamin D)

  • drospirenone (hormone replacement)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    ritonavir + drospirenone (hormone replacement)

    monitor potassium: combo may incr. or decr. drospirenone levels, incr. risk of hyperkalemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • dulaglutide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dulaglutide
    1 interaction

    Monitor/Modify Tx

    ritonavir + dulaglutide

    monitor HR, glucose; consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • edoxaban
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    ritonavir + edoxaban

    monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • elexacaftor/tezacaftor/ivacaftor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elexacaftor/ tezacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    ritonavir + elexacaftor/ tezacaftor/ ivacaftor

    2-5 YO: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to one packet 2x/wk (3-4 days apart), no ivacaftor evening doses; 6 YO AND OLDER: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to two tablets 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • eluxadoline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eluxadoline
    1 interaction

    Monitor/Modify Tx

    ritonavir + eluxadoline

    decr. eluxadoline dose to 75 mg bid: combo may incr. eluxadoline levels, risk of adverse effects (hepatic transport inhibited)

  • empagliflozin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    empagliflozin
    1 interaction

    Monitor/Modify Tx

    ritonavir + empagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • enfortumab vedotin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    ritonavir + enfortumab vedotin

    monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • ertugliflozin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ertugliflozin
    1 interaction

    Monitor/Modify Tx

    ritonavir + ertugliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • erythromycin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    ritonavir + erythromycin

    monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • esmolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + esmolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • eszopiclone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eszopiclone
    1 interaction

    Monitor/Modify Tx

    ritonavir + eszopiclone

    adjust eszopiclone max dose to 2 mg/day: combo may incr. eszopiclone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ethosuximide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ethosuximide
    1 interaction

    Monitor/Modify Tx

    ritonavir + ethosuximide

    monitor ethosuximide levels: combo may incr. ethosuximide levels, risk of toxicity (hepatic metabolism inhibited)

  • etripamil nasal
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etripamil nasal
    1 interaction

    Monitor/Modify Tx

    ritonavir + etripamil nasal

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • etuvetidigene autotemcel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    ritonavir + etuvetidigene autotemcel

    delay gene therapy initiation until western blot and viral load monitoring performed at 6mo post-exposure; discontinue ritonavir at least 1mo prior to mobilization; may resume ritonavir at least 7 days after etuvetidigene autotemcel infusion: combo may interfere with gene transfer into apheresed cells (antagonistic effects)

  • exenatide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    exenatide
    1 interaction

    Monitor/Modify Tx

    ritonavir + exenatide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • febuxostat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    febuxostat
    1 interaction

    Monitor/Modify Tx

    ritonavir + febuxostat

    monitor uric acid levels: combo may decr. febuxostat efficacy (antagonistic effects)

  • felodipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    ritonavir + felodipine

    monitor BP, HR; consider decr. felodipine dose: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

  • flurazepam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    flurazepam
    1 interaction

    Monitor/Modify Tx

    ritonavir + flurazepam

    monitor respiratory rate; consider decr. flurazepam dose: combo may incr. flurazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • fluvastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fluvastatin
    1 interaction

    Monitor/Modify Tx

    ritonavir + fluvastatin

    monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

  • fosamprenavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fosamprenavir
    2 interactions

    Monitor/Modify Tx

    ritonavir + fosamprenavir

    see fosamprenavir Adult/Peds Dosing for specific combo doses used for therapeutic advantage: ritonavir boosts fosamprenavir levels, efficacy (hepatic metabolism inhibited)

    Caution Advised

    nirmatrelvir + fosamprenavir

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • fostamatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    ritonavir + fostamatinib

    monitor BP, CBC, LFTs, consider decr. fostamatinib dose: combo may incr. fostamatinib active metabolite levels, risk of HTN, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • gadobenate dimeglumine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    gadobenate dimeglumine
    1 interaction

    Monitor/Modify Tx

    ritonavir + gadobenate dimeglumine

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • galantamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    galantamine
    1 interaction

    Monitor/Modify Tx

    ritonavir + galantamine

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • glimepiride
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glimepiride
    1 interaction

    Monitor/Modify Tx

    ritonavir + glimepiride

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • glipizide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glipizide
    1 interaction

    Monitor/Modify Tx

    ritonavir + glipizide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • glyburide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glyburide
    1 interaction

    Monitor/Modify Tx

    ritonavir + glyburide

    monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects; may decr. antidiabetic agent efficacy (hepatic transport inhibited; antagonistic effects)

  • guanfacine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    ritonavir + guanfacine

    monitor HR, consider monitoring ECG; decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • haloperidol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    ritonavir + haloperidol

    monitor ECG; consider haloperidol dose adjustment: combo may incr. or decr. haloperidol levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • hydrocortisone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    ritonavir + hydrocortisone

    consider decr. hydrocortisone dose; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • ibrexafungerp
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ibrexafungerp
    1 interaction

    Monitor/Modify Tx

    ritonavir + ibrexafungerp

    decr. ibrexafungerp dose to 150 mg q12h: combo may incr. ibrexafungerp levels, risk of adverse effects (hepatic metabolism inhibited)

  • ifosfamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    ritonavir + ifosfamide

    monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels or decr. ifosfamide active metabolite levels, incr. risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects or decr. efficacy (hepatic metabolism altered, incr. or decr. active metabolite formation)

  • iloperidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    ritonavir + iloperidone

    monitor ECG; decr. iloperidone dose 50%: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • imatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    ritonavir + imatinib

    monitor CBC: combo may incr. imatinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • imipramine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    ritonavir + imipramine

    monitor imipramine levels: combo may decr. imipramine levels, efficacy (hepatic metabolism induced)

  • insulin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    ritonavir + insulin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • istradefylline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    istradefylline
    1 interaction

    Monitor/Modify Tx

    ritonavir + istradefylline

    adjust max istradefylline dose to 20 mg/day: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

  • itraconazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    itraconazole
    1 interaction

    Monitor/Modify Tx

    ritonavir + itraconazole

    ITRACONAZOLE 100 MG CAP: adjust itraconazole dose to max 200 mg/day; ITRACONAZOLE 65 MG CAP: consider decr. itraconazole dose: combo may incr. itraconazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • ketoconazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ketoconazole
    1 interaction

    Monitor/Modify Tx

    ritonavir + ketoconazole

    adjust ketoconazole dose to max 200 mg/day: combo may incr. ketoconazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • labetalol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    ritonavir + labetalol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lacosamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lacosamide
    1 interaction

    Monitor/Modify Tx

    ritonavir + lacosamide

    monitor HR, ECG, especially during lacosamide initiation/titration; consider decr. lacosamide dose if also renal or hepatic impairment: combo may incr. lacosamide levels, risk of PR interval prolongation, AV block, bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lamotrigine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lamotrigine
    1 interaction

    Monitor/Modify Tx

    ritonavir + lamotrigine

    monitor HR; consider incr. lamotrigine maint. dose, initial dose escalation unchanged: combo may decr. lamotrigine levels, efficacy; may incr. risk of bradycardia (UGT induced; additive effects)

  • lanreotide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    ritonavir + lanreotide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • levobunolol ophthalmic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levobunolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    ritonavir + levobunolol ophthalmic

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • levomilnacipran
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    ritonavir + levomilnacipran

    adjust levomilnacipran max dose to 80 mg/day: combo may incr. levomilnacipran levels, risk of adverse effects (hepatic metabolism inhibited)

  • levothyroxine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    ritonavir + levothyroxine

    monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

  • lidocaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    ritonavir + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited, additive effects)

  • linagliptin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    linagliptin
    1 interaction

    Monitor/Modify Tx

    ritonavir + linagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • liothyronine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    ritonavir + liothyronine

    monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

  • liraglutide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    liraglutide
    1 interaction

    Monitor/Modify Tx

    ritonavir + liraglutide

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • lisdexamfetamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    ritonavir + lisdexamfetamine

    monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism possibly inhibited)

  • lixisenatide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lixisenatide
    1 interaction

    Monitor/Modify Tx

    ritonavir + lixisenatide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • loperamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    loperamide
    1 interaction

    Monitor/Modify Tx

    ritonavir + loperamide

    monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lumateperone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    ritonavir + lumateperone

    monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • maraviroc
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    maraviroc
    1 interaction

    Monitor/Modify Tx

    ritonavir + maraviroc

    ADULTS: adjust maraviroc dose to 150 mg bid, even if also combined w/ potent CYP3A4 inducer; PEDS: see maraviroc pkg insert for age/wt-based dose adjustments: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited, MRP2-mediated transport inhibited, P-gp-mediated transport inhibited)

  • mavorixafor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mavorixafor
    1 interaction

    Monitor/Modify Tx

    ritonavir + mavorixafor

    decr. mavorixafor dose to 200 mg qd: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • mepivacaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mepivacaine
    1 interaction

    Monitor/Modify Tx

    ritonavir + mepivacaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • metformin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    metformin
    1 interaction

    Monitor/Modify Tx

    ritonavir + metformin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • methadone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    ritonavir + methadone

    monitor for withdrawal sx; consider methadone dose adjustment: combo may decr. methadone levels, efficacy (hepatic metabolism induced)

  • methamphetamine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    ritonavir + methamphetamine

    monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. methamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism possibly inhibited)

  • methotrexate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    ritonavir + methotrexate

    monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited)

  • metoprolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + metoprolol

    monitor BP, HR, ECG; consider lower metoprolol dose: combo may incr. metoprolol levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mexiletine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mexiletine
    1 interaction

    Monitor/Modify Tx

    ritonavir + mexiletine

    monitor ECG; consider monitoring mexiletine levels: combo may incr. mexiletine levels, risk of adverse effects; may incr. risk of cardiac and neurologic events (hepatic metabolism inhibited; additive effects)

  • midodrine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    midodrine
    1 interaction

    Monitor/Modify Tx

    ritonavir + midodrine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • miglitol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    miglitol
    2 interactions

    Monitor/Modify Tx

    ritonavir + miglitol

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • milsaperidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    milsaperidone
    2 interactions

    Monitor/Modify Tx

    ritonavir + milsaperidone

    monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • mirtazapine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mirtazapine
    2 interactions

    Monitor/Modify Tx

    ritonavir + mirtazapine

    monitor ECG: combo may incr. mirtazapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • mitoxantrone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mitoxantrone
    2 interactions

    Monitor/Modify Tx

    ritonavir + mitoxantrone

    monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport inhibited)

  • momelotinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    momelotinib
    1 interaction

    Monitor/Modify Tx

    ritonavir + momelotinib

    monitor CBC, bleeding s/sx: combo may incr. momelotinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic transport inhibited)

  • morphine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    morphine
    2 interactions

    Monitor/Modify Tx

    ritonavir + morphine

    monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

  • mycophenolate mofetil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mycophenolate mofetil
    2 interactions

    Monitor/Modify Tx

    ritonavir + mycophenolate mofetil

    consider monitoring mycophenolic acid levels: combo may decr. mycophenolic acid levels, efficacy (UGT induced)

  • nadolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nadolol
    2 interactions

    Monitor/Modify Tx

    ritonavir + nadolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • nateglinide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nateglinide
    2 interactions

    Monitor/Modify Tx

    ritonavir + nateglinide

    monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects; may decr. antidiabetic agent efficacy (hepatic transport inhibited; antagonistic effects)

  • nefazodone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nefazodone
    2 interactions

    Monitor/Modify Tx

    ritonavir + nefazodone

    consider decr. nefazodone dose: combo may incr. nefazodone levels, risk of adverse effects; may incr. risk of cardiac, neurologic events (hepatic metabolism possibly inhibited; additive effects)

  • neostigmine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    neostigmine
    2 interactions

    Monitor/Modify Tx

    ritonavir + neostigmine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • nerandomilast
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nerandomilast
    2 interactions

    Monitor/Modify Tx

    ritonavir + nerandomilast

    decr. nerandomilast dose to 9 mg twice daily: combo may incr. nerandomilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • nicardipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nicardipine
    2 interactions

    Monitor/Modify Tx

    ritonavir + nicardipine

    monitor BP; consider decr. nicardipine dose: combo may incr. nicardipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nifedipine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nifedipine
    2 interactions

    Monitor/Modify Tx

    ritonavir + nifedipine

    monitor BP; consider decr. nifedipine dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nintedanib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nintedanib
    2 interactions

    Monitor/Modify Tx

    ritonavir + nintedanib

    consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (hepatic metabolism inhibited)

  • octreotide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    octreotide
    2 interactions

    Monitor/Modify Tx

    ritonavir + octreotide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • olanzapine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    olanzapine
    2 interactions

    Monitor/Modify Tx

    ritonavir + olanzapine

    if given in combo w/ samidorphan, consider olanzapine dose adjustment; otherwise, caution advised: combo may decr. olanzapine levels, efficacy (hepatic metabolism induced)

  • oxcarbazepine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    oxcarbazepine
    3 interactions

    Monitor/Modify Tx

    ritonavir + oxcarbazepine

    monitor 10-hydroxyoxcarbazepine levels: combo may decr. ritonavir, oxcarbazepine active metabolite levels, efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport possibly induced)

    Caution Advised

    nirmatrelvir + oxcarbazepine

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • paclitaxel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    paclitaxel
    2 interactions

    Monitor/Modify Tx

    ritonavir + paclitaxel

    monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • paltusotine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    paltusotine
    2 interactions

    Monitor/Modify Tx

    ritonavir + paltusotine

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • paroxetine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    paroxetine
    2 interactions

    Monitor/Modify Tx

    ritonavir + paroxetine

    consider decr. paroxetine dose: combo may incr. paroxetine levels, risk of adverse effects (hepatic metabolism inhibited)

  • pasireotide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pasireotide
    2 interactions

    Monitor/Modify Tx

    ritonavir + pasireotide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • perphenazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    perphenazine
    2 interactions

    Monitor/Modify Tx

    ritonavir + perphenazine

    consider decr. perphenazine dose: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

  • pimavanserin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pimavanserin
    2 interactions

    Monitor/Modify Tx

    ritonavir + pimavanserin

    monitor ECG; decr. pimavanserin dose to 10 mg qd: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • pindolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pindolol
    2 interactions

    Monitor/Modify Tx

    ritonavir + pindolol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • pioglitazone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pioglitazone
    1 interaction

    Monitor/Modify Tx

    ritonavir + pioglitazone

    monitor glucose: combo may decr. ritonavir levels, efficacy; may decr. antidiabetic agent efficacy (hepatic metabolism induced; antagonistic effects)

    Caution Advised

    nirmatrelvir + pioglitazone

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • polatuzumab vedotin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    polatuzumab vedotin
    2 interactions

    Monitor/Modify Tx

    ritonavir + polatuzumab vedotin

    monitor CBC, LFTs: combo may incr. polatuzumab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • pramlintide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pramlintide
    2 interactions

    Monitor/Modify Tx

    ritonavir + pramlintide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • pravastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pravastatin
    2 interactions

    Monitor/Modify Tx

    ritonavir + pravastatin

    monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

  • probenecid
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    probenecid
    2 interactions

    Monitor/Modify Tx

    ritonavir + probenecid

    monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)

  • procainamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    procainamide
    2 interactions

    Monitor/Modify Tx

    ritonavir + procainamide

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • propranolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    ritonavir + propranolol

    monitor BP, HR; consider monitoring ECG: combo may incr. or decr. propranolol levels, incr. risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects or decr. efficacy (hepatic metabolism altered, additive effects)

  • pyridostigmine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pyridostigmine
    2 interactions

    Monitor/Modify Tx

    ritonavir + pyridostigmine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    quinidine (CYP2D6 inhibitor)
    2 interactions

    Monitor/Modify Tx

    ritonavir + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • rasburicase
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rasburicase
    1 interaction

    Monitor/Modify Tx

    ritonavir + rasburicase

    monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)

  • regadenoson
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    regadenoson
    2 interactions

    Monitor/Modify Tx

    ritonavir + regadenoson

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • remifentanil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    remifentanil
    2 interactions

    Monitor/Modify Tx

    ritonavir + remifentanil

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • repaglinide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    repaglinide
    2 interactions

    Monitor/Modify Tx

    ritonavir + repaglinide

    monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects; may decr. antidiabetic agent efficacy (hepatic metabolism inhibited, hepatic transport inhibited; antagonistic effects)

  • revumenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    revumenib
    2 interactions

    Monitor/Modify Tx

    ritonavir + revumenib

    monitor ECG, electrolytes; WEIGHT 40 KG OR MORE: decr. revumenib dose to 160 mg bid; WEIGHT <40 KG: decr. revumenib dose to 95 mg/m^2 bid: combo may incr. revumenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • rilpivirine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rilpivirine
    2 interactions

    Monitor/Modify Tx

    ritonavir + rilpivirine

    monitor ECG: combo may incr. rilpivirine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • risperidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    risperidone
    2 interactions

    Monitor/Modify Tx

    ritonavir + risperidone

    consider decr. risperidone dose: combo may incr. risperidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • rivastigmine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rivastigmine
    2 interactions

    Monitor/Modify Tx

    ritonavir + rivastigmine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • romidepsin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    romidepsin
    2 interactions

    Monitor/Modify Tx

    ritonavir + romidepsin

    monitor ECG, CBC; consider romidepsin dose adjustment: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ropinirole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ropinirole
    2 interactions

    Monitor/Modify Tx

    ritonavir + ropinirole

    consider ropinirole dose adjustment: combo may decr. ropinirole levels, efficacy (hepatic metabolism induced)

  • ropivacaine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ropivacaine
    2 interactions

    Monitor/Modify Tx

    ritonavir + ropivacaine

    monitor HR: combo may decr. ropivacaine levels, efficacy; may incr. risk of bradycardia (hepatic metabolism induced; additive effects)

  • rosiglitazone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rosiglitazone
    1 interaction

    Monitor/Modify Tx

    ritonavir + rosiglitazone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • rosuvastatin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rosuvastatin
    2 interactions

    Monitor/Modify Tx

    ritonavir + rosuvastatin

    monitor CK, myopathy sx; use lowest rosuvastatin dose: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

  • saxagliptin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    saxagliptin
    2 interactions

    Monitor/Modify Tx

    ritonavir + saxagliptin

    monitor glucose; adjust max saxagliptin dose to 2.5 mg/day: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects; may decr. antidiabetic agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • semaglutide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    semaglutide
    2 interactions

    Monitor/Modify Tx

    ritonavir + semaglutide

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • sitagliptin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sitagliptin
    2 interactions

    Monitor/Modify Tx

    ritonavir + sitagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • solifenacin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    solifenacin
    2 interactions

    Monitor/Modify Tx

    ritonavir + solifenacin

    monitor ECG; adjust solifenacin dose as follows: pts 9-15 kg: max 2 mg/day; pts 16-45 kg: max 3 mg/day; pts 46-60 kg: max 4 mg/day; pts >60 kg or adult pts: max 5 mg/day: combo may incr. solifenacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • sotalol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sotalol
    2 interactions

    Monitor/Modify Tx

    ritonavir + sotalol

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • stiripentol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    ritonavir + stiripentol

    consider stiripentol dose adjustment: combo may decr. levels, efficacy of both drugs (hepatic metabolism possibly induced)

    Caution Advised

    nirmatrelvir + stiripentol

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

  • succinylcholine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    succinylcholine
    2 interactions

    Monitor/Modify Tx

    ritonavir + succinylcholine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • sugammadex
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sugammadex
    2 interactions

    Monitor/Modify Tx

    ritonavir + sugammadex

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • tacrolimus
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tacrolimus
    2 interactions

    Monitor/Modify Tx

    ritonavir + tacrolimus

    monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • tenofovir alafenamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tenofovir alafenamide
    2 interactions

    Monitor/Modify Tx

    ritonavir + tenofovir alafenamide

    if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

  • tenofovir disoproxil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tenofovir disoproxil
    2 interactions

    Monitor/Modify Tx

    ritonavir + tenofovir disoproxil

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

  • tezacaftor/ivacaftor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tezacaftor/ ivacaftor
    2 interactions

    Monitor/Modify Tx

    ritonavir + tezacaftor/ ivacaftor

    decr. tezacaftor/ivacaftor morning dose to 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • thalidomide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    thalidomide
    2 interactions

    Monitor/Modify Tx

    ritonavir + thalidomide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • theophylline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    theophylline
    2 interactions

    Monitor/Modify Tx

    ritonavir + theophylline

    monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metabolism induced)

  • tiagabine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tiagabine
    2 interactions

    Monitor/Modify Tx

    ritonavir + tiagabine

    consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy (hepatic metabolism induced; further induction possible if on concurrent enzyme-inducing AEDs)

  • timolol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    timolol
    2 interactions

    Monitor/Modify Tx

    ritonavir + timolol

    monitor HR, consider monitoring ECG: combo may incr. timolol levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

  • timolol ophthalmic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    timolol ophthalmic
    2 interactions

    Monitor/Modify Tx

    ritonavir + timolol ophthalmic

    monitor HR, consider monitoring ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • tirzepatide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tirzepatide
    2 interactions

    Monitor/Modify Tx

    ritonavir + tirzepatide

    monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • tofacitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tofacitinib
    2 interactions

    Monitor/Modify Tx

    ritonavir + tofacitinib

    ALL USES: monitor CBC; ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. tofacitinib dose to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. tofacitinib induction to 5 mg tablet bid or 11 mg XR tablet qd for up to 16 wks, then 5 mg tablet qd maintenance; do not use XR tablet for maintenance; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • tolterodine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tolterodine
    2 interactions

    Monitor/Modify Tx

    ritonavir + tolterodine

    adjust tolterodine dose to max 2 mg/day: combo may incr. tolterodine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • upadacitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    upadacitinib
    2 interactions

    Monitor/Modify Tx

    ritonavir + upadacitinib

    monitor CBC; ATOPIC DERMATITIS: limit upadacitinib dose to 15 mg qd; CROHN DZ: limit upadacitinib induction dose to 30 mg qd x12wk, followed by 15 mg qd maintenance; ULCERATIVE COLITIS: limit upadacitinib induction dose to 30 mg qd x8wk, followed by 15 mg qd maintenance; ALL OTHER INDICATIONS: no dose adjustment: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • valproic acid
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    valproic acid
    2 interactions

    Monitor/Modify Tx

    ritonavir + valproic acid

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • valsartan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    valsartan
    2 interactions

    Monitor/Modify Tx

    ritonavir + valsartan

    monitor potassium: combo may incr. valsartan levels, risk of hyperkalemia, other adverse effects (MRP2-mediated transport inhibited)

  • vamorolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vamorolone
    3 interactions

    Monitor/Modify Tx

    ritonavir + vamorolone

    decr. vamorolone dose to 4 mg/kg qd, up to max 200 mg/day for pts >50kg: combo may incr. vamorolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

    Caution Advised

    nirmatrelvir + vamorolone

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

  • verapamil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    verapamil
    2 interactions

    Monitor/Modify Tx

    ritonavir + verapamil

    monitor BP, HR, consider monitoring ECG; consider decr. verapamil dose: combo may incr. verapamil levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vilanterol inhaled
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vilanterol inhaled
    2 interactions

    Monitor/Modify Tx

    ritonavir + vilanterol inhaled

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

  • warfarin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    warfarin
    2 interactions

    Monitor/Modify Tx

    ritonavir + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. or decr. warfarin levels, incr. risk of bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism altered)

  • zanubrutinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zanubrutinib
    3 interactions

    Monitor/Modify Tx

    ritonavir + zanubrutinib

    decr. zanubrutinib dose to 80 mg qd; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    Caution Advised

    nirmatrelvir + zanubrutinib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

  • ziftomenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ziftomenib
    2 interactions

    Monitor/Modify Tx

    ritonavir + ziftomenib

    monitor ECG: combo may incr. or decr. ziftomenib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • zuranolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zuranolone
    2 interactions

    Monitor/Modify Tx

    ritonavir + zuranolone

    decr. zuranolone dose to 30 mg qd: combo may incr. zuranolone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

Caution Advised

  • albendazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    albendazole
    2 interactions

    Caution Advised

    ritonavir + albendazole

    caution advised: combo may decr. albendazole levels, efficacy (hepatic metabolism induced)

  • alosetron
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    alosetron
    1 interaction

    Caution Advised

    ritonavir + alosetron

    caution advised: combo may incr. or decr. alosetron levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • anagrelide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    anagrelide
    2 interactions

    Caution Advised

    ritonavir + anagrelide

    caution advised: combo may decr. anagrelide levels, efficacy (hepatic metabolism induced)

  • armodafinil
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    armodafinil
    3 interactions

    Caution Advised

    nirmatrelvir + armodafinil

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + armodafinil

    caution advised: combo may decr. ritonavir levels, efficacy; may incr. armodafinil levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • artesunate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    artesunate
    1 interaction

    Caution Advised

    ritonavir + artesunate

    caution advised: combo may decr. dihydroartemisinin levels, efficacy (UGT induced; artesunate converted to dihydroartemisinin by esterases)

  • bazedoxifene
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bazedoxifene
    2 interactions

    Caution Advised

    ritonavir + bazedoxifene

    caution advised: combo may decr. bazedoxifene levels, efficacy (UGT induced)

  • belzutifan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    belzutifan
    3 interactions

    Caution Advised

    nirmatrelvir + belzutifan

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + belzutifan

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • bexarotene
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bexarotene
    3 interactions

    Caution Advised

    nirmatrelvir + bexarotene

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + bexarotene

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • bictegravir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bictegravir
    1 interaction

    Caution Advised

    ritonavir + bictegravir

    caution advised: combo may incr. bictegravir levels, risk of adverse effects (hepatic metabolism inhibited)

  • bupropion
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    bupropion
    2 interactions

    Caution Advised

    ritonavir + bupropion

    caution advised: combo may decr. bupropion and metabolite levels, efficacy (hepatic metabolism induced)

  • caffeine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    caffeine
    2 interactions

    Caution Advised

    ritonavir + caffeine

    caution advised: combo may decr. caffeine levels, efficacy (hepatic metabolism induced)

  • cannabis
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cannabis
    2 interactions

    Caution Advised

    ritonavir + cannabis

    caution advised: combo may incr. cannabis levels, risk of adverse effects (hepatic metabolism inhibited)

  • capmatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    capmatinib
    2 interactions

    Caution Advised

    ritonavir + capmatinib

    caution advised: combo may incr. or decr. capmatinib levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • carisoprodol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    carisoprodol
    2 interactions

    Caution Advised

    ritonavir + carisoprodol

    caution advised: combo may decr. carisoprodol levels, incr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism induced, incr. conversion to active metabolite)

  • chlordiazepoxide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    chlordiazepoxide
    2 interactions

    Caution Advised

    ritonavir + chlordiazepoxide

    caution advised: combo may incr. chlordiazepoxide levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • chlorpromazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    chlorpromazine
    1 interaction

    Caution Advised

    ritonavir + chlorpromazine

    caution advised: combo may decr. chlorpromazine levels, efficacy (hepatic metabolism induced)

  • clindamycin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clindamycin
    2 interactions

    Caution Advised

    ritonavir + clindamycin

    caution advised: combo may incr. clindamycin levels, risk of adverse effects (hepatic metabolism inhibited)

  • clobazam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clobazam
    3 interactions

    Caution Advised

    nirmatrelvir + clobazam

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + clobazam

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • clomipramine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    clomipramine
    2 interactions

    Caution Advised

    ritonavir + clomipramine

    caution advised: combo may decr. clomipramine levels, efficacy (hepatic metabolism induced)

  • cortisone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cortisone
    1 interaction

    Caution Advised

    ritonavir + cortisone

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. cortisone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • cyclobenzaprine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    cyclobenzaprine
    2 interactions

    Caution Advised

    ritonavir + cyclobenzaprine

    caution advised: combo may decr. cyclobenzaprine levels, efficacy (hepatic metabolism induced)

  • danshen
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    danshen
    3 interactions

    Caution Advised

    nirmatrelvir + danshen

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + danshen

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

  • darolutamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    darolutamide
    2 interactions

    Caution Advised

    nirmatrelvir + darolutamide

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + darolutamide

    caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited; hepatic metabolism induced)

  • dicloxacillin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dicloxacillin
    2 interactions

    Caution Advised

    nirmatrelvir + dicloxacillin

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + dicloxacillin

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

  • doravirine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    doravirine
    1 interaction

    Caution Advised

    ritonavir + doravirine

    caution advised: combo may incr. doravirine levels, risk of adverse effects (hepatic metabolism inhibited)

  • doxazosin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    doxazosin
    1 interaction

    Caution Advised

    ritonavir + doxazosin

    caution advised: combo may incr. doxazosin levels, risk of adverse effects (hepatic metabolism inhibited)

  • dronabinol
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dronabinol
    1 interaction

    Caution Advised

    ritonavir + dronabinol

    caution advised: combo may incr. dronabinol levels, risk of adverse effects (hepatic metabolism inhibited)

  • duloxetine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    duloxetine
    1 interaction

    Caution Advised

    ritonavir + duloxetine

    caution advised: combo may decr. duloxetine levels, efficacy (hepatic metabolism induced)

  • dutasteride
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    dutasteride
    1 interaction

    Caution Advised

    ritonavir + dutasteride

    caution advised: combo may incr. dutasteride levels, risk of adverse effects (hepatic metabolism inhibited)

  • echinacea
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    echinacea
    3 interactions

    Caution Advised

    nirmatrelvir + echinacea

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + echinacea

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • elafibranor
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    elafibranor
    2 interactions

    Caution Advised

    nirmatrelvir + elafibranor

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + elafibranor

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • enasidenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    enasidenib
    2 interactions

    Caution Advised

    nirmatrelvir + enasidenib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + enasidenib

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • entacapone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    entacapone
    1 interaction

    Caution Advised

    ritonavir + entacapone

    caution advised: combo may decr. entacapone levels, efficacy (UGT induced)

  • eravacycline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eravacycline
    1 interaction

    Caution Advised

    ritonavir + eravacycline

    caution advised: combo may incr. eravacycline levels, risk of adverse effects (hepatic metabolism inhibited)

  • eslicarbazepine acetate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    eslicarbazepine acetate
    3 interactions

    Caution Advised

    nirmatrelvir + eslicarbazepine acetate

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + eslicarbazepine acetate

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • esomeprazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    esomeprazole
    1 interaction

    Caution Advised

    ritonavir + esomeprazole

    caution advised: combo may decr. esomeprazole levels, efficacy (hepatic metabolism induced)

  • estradiol (hormone replacement)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    estradiol (hormone replacement)
    1 interaction

    Caution Advised

    ritonavir + estradiol (hormone replacement)

    caution advised: combo may incr. or decr. estradiol levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • estrogens, conjugated (hormone replacement)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    estrogens, conjugated (hormone replacement)
    1 interaction

    Caution Advised

    ritonavir + estrogens, conjugated (hormone replacement)

    caution advised: combo may decr. estrogen levels, efficacy (hepatic metabolism induced)

  • estrogens, esterified (hormone replacement)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Caution Advised

    ritonavir + estrogens, esterified (hormone replacement)

    caution advised: combo may incr. or decr. estrogen levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • ethinyl estradiol (hormone replacement)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Caution Advised

    ritonavir + ethinyl estradiol (hormone replacement)

    caution advised: combo may incr. or decr. ethinyl estradiol levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • felbamate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    felbamate
    2 interactions

    Caution Advised

    nirmatrelvir + felbamate

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + felbamate

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • fenfluramine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fenfluramine
    1 interaction

    Caution Advised

    ritonavir + fenfluramine

    caution advised: combo may decr. fenfluramine levels, efficacy (hepatic metabolism induced)

  • fludrocortisone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fludrocortisone
    1 interaction

    Caution Advised

    ritonavir + fludrocortisone

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. fludrocortisone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • fluphenazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fluphenazine
    1 interaction

    Caution Advised

    ritonavir + fluphenazine

    caution advised: combo may decr. fluphenazine levels, efficacy (hepatic metabolism induced)

  • fluticasone furoate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fluticasone furoate
    1 interaction

    Caution Advised

    ritonavir + fluticasone furoate

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • fruquintinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    fruquintinib
    2 interactions

    Caution Advised

    ritonavir + fruquintinib

    caution advised: combo may decr. fruquintinib levels, efficacy (hepatic metabolism induced)

  • garlic
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    garlic
    2 interactions

    Caution Advised

    nirmatrelvir + garlic

    caution advised w/ supplemental garlic; dietary intake OK: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + garlic

    caution advised w/ supplemental garlic; dietary intake OK: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • gefitinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    gefitinib
    1 interaction

    Caution Advised

    ritonavir + gefitinib

    caution advised: combo may incr. gefitinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • ginkgo
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ginkgo
    3 interactions

    Caution Advised

    nirmatrelvir + ginkgo

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + ginkgo

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • ginseng, Asian
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ginseng, Asian
    2 interactions

    Caution Advised

    nirmatrelvir + ginseng, Asian

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + ginseng, Asian

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • glycerol phenylbutyrate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    glycerol phenylbutyrate
    2 interactions

    Caution Advised

    nirmatrelvir + glycerol phenylbutyrate

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + glycerol phenylbutyrate

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • griseofulvin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    griseofulvin
    2 interactions

    Caution Advised

    nirmatrelvir + griseofulvin

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + griseofulvin

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • hydromorphone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    hydromorphone
    2 interactions

    Caution Advised

    ritonavir + hydromorphone

    caution advised: combo may decr. hydromorphone levels, efficacy (UGT induced)

  • lansoprazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lansoprazole
    1 interaction

    Caution Advised

    ritonavir + lansoprazole

    caution advised: combo may decr. lansoprazole levels, efficacy (hepatic metabolism induced)

  • lazertinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lazertinib
    1 interaction

    Caution Advised

    ritonavir + lazertinib

    caution advised: combo may decr. lazertinib levels, efficacy (hepatic metabolism induced)

  • lenacapavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    lenacapavir
    2 interactions

    Caution Advised

    ritonavir + lenacapavir

    caution advised: combo may incr. or decr. lenacapavir levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited; hepatic metabolism induced, UGT induced)

  • levonorgestrel intrauterine device (contraceptive)
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    levonorgestrel intrauterine device (contraceptive)
    1 interaction

    Caution Advised

    ritonavir + levonorgestrel intrauterine device (contraceptive)

    caution advised: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • melatonin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    melatonin
    1 interaction

    Caution Advised

    ritonavir + melatonin

    caution advised: combo may decr. melatonin levels, efficacy (hepatic metabolism induced)

  • meropenem
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    meropenem
    2 interactions

    Caution Advised

    nirmatrelvir + meropenem

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

    ritonavir + meropenem

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism possibly induced, P-gp-mediated transport possibly induced)

  • mirvetuximab soravtansine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mirvetuximab soravtansine
    2 interactions

    Caution Advised

    ritonavir + mirvetuximab soravtansine

    caution advised: combo may incr. microtubule inhibitor (DM4) levels, risk of adverse effects (hepatic metabolism inhibited)

  • mometasone implant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mometasone implant
    1 interaction

    Caution Advised

    ritonavir + mometasone implant

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. mometasone levels, risk of systemic corticosteroid effects including Cushing syndrome, adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • moxifloxacin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    moxifloxacin
    1 interaction

    Caution Advised

    ritonavir + moxifloxacin

    caution advised: combo may decr. moxifloxacin levels, efficacy (UGT induced)

  • mycophenolic acid
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    mycophenolic acid
    1 interaction

    Caution Advised

    ritonavir + mycophenolic acid

    caution advised: combo may decr. mycophenolic acid levels, efficacy (UGT induced)

  • naldemedine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    naldemedine
    2 interactions

    Caution Advised

    ritonavir + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • nelfinavir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nelfinavir
    1 interaction

    Caution Advised

    ritonavir + nelfinavir

    caution advised, doses not established for combo use: combo may incr. nelfinavir levels, risk of adverse effects (hepatic metabolism inhibited)

  • netupitant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    netupitant
    1 interaction

    Caution Advised

    ritonavir + netupitant

    caution advised: combo may decr. netupitant levels, efficacy (hepatic metabolism induced)

  • nevirapine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    nevirapine
    2 interactions

    Caution Advised

    nirmatrelvir + nevirapine

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + nevirapine

    caution advised: combo may incr. or decr. nevirapine levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • odevixibat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    odevixibat
    3 interactions

    Caution Advised

    nirmatrelvir + odevixibat

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + odevixibat

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • olutasidenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    olutasidenib
    1 interaction

    Caution Advised

    nirmatrelvir + olutasidenib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

    ritonavir + olutasidenib

    caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

  • ospemifene
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ospemifene
    1 interaction

    Caution Advised

    ritonavir + ospemifene

    caution advised: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

  • oxybutynin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    oxybutynin
    1 interaction

    Caution Advised

    ritonavir + oxybutynin

    caution advised: combo may incr. oxybutynin levels, risk of adverse effects (hepatic metabolism inhibited)

  • pentoxifylline
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pentoxifylline
    2 interactions

    Caution Advised

    ritonavir + pentoxifylline

    caution advised: combo may decr. pentoxifylline levels, efficacy (hepatic metabolism induced)

  • perampanel
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    perampanel
    3 interactions

    Caution Advised

    nirmatrelvir + perampanel

    caution advised if on perampanel 12 mg/day: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + perampanel

    caution advised: combo may decr. perampanel levels, efficacy; may decr. ritonavir levels, efficacy if on perampanel 12 mg/day (hepatic metabolism induced)

  • pimecrolimus topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pimecrolimus topical
    1 interaction

    Caution Advised

    ritonavir + pimecrolimus topical

    caution advised: combo may incr. pimecrolimus levels, risk of serious infection, other adverse effects (hepatic metabolism possibly inhibited)

  • pirfenidone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pirfenidone
    1 interaction

    Caution Advised

    ritonavir + pirfenidone

    caution advised: combo may decr. pirfenidone levels, efficacy (hepatic metabolism induced)

  • pomalidomide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pomalidomide
    1 interaction

    Caution Advised

    ritonavir + pomalidomide

    caution advised: combo may decr. pomalidomide levels, efficacy (hepatic metabolism induced)

  • prednisolone
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    prednisolone
    2 interactions

    Caution Advised

    ritonavir + prednisolone

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. prednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • pretomanid
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    pretomanid
    1 interaction

    Caution Advised

    ritonavir + pretomanid

    caution advised: combo may decr. pretomanid levels, efficacy (hepatic metabolism induced)

  • raltegravir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    raltegravir
    1 interaction

    Caution Advised

    ritonavir + raltegravir

    caution advised: combo may decr. raltegravir levels, efficacy (UGT induced)

  • ramelteon
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ramelteon
    1 interaction

    Caution Advised

    ritonavir + ramelteon

    caution advised: combo may incr. or decr. ramelteon levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • riluzole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    riluzole
    2 interactions

    Caution Advised

    ritonavir + riluzole

    caution advised: combo may decr. riluzole levels, efficacy (hepatic metabolism induced)

  • ripretinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    ripretinib
    1 interaction

    Caution Advised

    ritonavir + ripretinib

    caution advised: combo may incr. or decr. ripretinib and active metabolite levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

  • roflumilast topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    ritonavir + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • rolapitant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rolapitant
    1 interaction

    Caution Advised

    ritonavir + rolapitant

    caution advised: combo may decr. rolapitant levels, efficacy (hepatic metabolism induced)

  • rufinamide
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    rufinamide
    3 interactions

    Caution Advised

    nirmatrelvir + rufinamide

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + rufinamide

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • samidorphan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    samidorphan
    1 interaction

    Caution Advised

    ritonavir + samidorphan

    caution advised: combo may decr. samidorphan levels, efficacy (hepatic metabolism induced)

  • sarilumab
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sarilumab
    2 interactions

    Caution Advised

    nirmatrelvir + sarilumab

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

    ritonavir + sarilumab

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

  • seladelpar
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    seladelpar
    2 interactions

    Caution Advised

    ritonavir + seladelpar

    caution advised: combo may incr. seladelpar levels, risk of adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited, hepatic transport inhibited)

  • selexipag
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    selexipag
    1 interaction

    Caution Advised

    ritonavir + selexipag

    caution advised: combo may decr. selexipag active metabolite levels, efficacy (UGT induced)

  • sirolimus topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    ritonavir + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • sulfasalazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    sulfasalazine
    1 interaction

    Caution Advised

    ritonavir + sulfasalazine

    caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)

  • tacrolimus topical
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tacrolimus topical
    1 interaction

    Caution Advised

    ritonavir + tacrolimus topical

    caution advised: combo may incr. tacrolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • tamoxifen
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tamoxifen
    1 interaction

    Caution Advised

    ritonavir + tamoxifen

    caution advised: combo may incr. tamoxifen levels, risk of adverse effects, decr. active tamoxifen metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • tecovirimat
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tecovirimat
    2 interactions

    Caution Advised

    nirmatrelvir + tecovirimat

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + tecovirimat

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • telisotuzumab vedotin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    telisotuzumab vedotin
    1 interaction

    Caution Advised

    ritonavir + telisotuzumab vedotin

    caution advised: combo may incr. telisotuzumab vedotin levels, risk of peripheral neuropathy, other adverse effects (hepatic metabolism inhibited)

  • telotristat ethyl
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    telotristat ethyl
    2 interactions

    Caution Advised

    nirmatrelvir + telotristat ethyl

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + telotristat ethyl

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • tinidazole
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tinidazole
    1 interaction

    Caution Advised

    ritonavir + tinidazole

    caution advised: combo may incr. tinidazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • tisotumab vedotin
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tisotumab vedotin
    1 interaction

    Caution Advised

    ritonavir + tisotumab vedotin

    caution advised: combo may incr. active moiety MMAE levels, risk of ocular toxicity, peripheral neuropathy, other adverse effects (hepatic metabolism inhibited)

  • tizanidine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tizanidine
    1 interaction

    Caution Advised

    ritonavir + tizanidine

    caution advised: combo may decr. tizanidine levels, efficacy (hepatic metabolism induced)

  • tocilizumab
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tocilizumab
    1 interaction

    Caution Advised

    nirmatrelvir + tocilizumab

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

    ritonavir + tocilizumab

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

  • topiramate
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    topiramate
    2 interactions

    Caution Advised

    nirmatrelvir + topiramate

    caution advised especially w/ topiramate doses >200 mg/day: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + topiramate

    caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. ritonavir levels, efficacy; may incr. topiramate levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • tovorafenib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tovorafenib
    2 interactions

    Caution Advised

    nirmatrelvir + tovorafenib

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

    ritonavir + tovorafenib

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

  • tradipitant
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tradipitant
    2 interactions

    Caution Advised

    ritonavir + tradipitant

    caution advised: combo may incr. tradipitant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • trifluoperazine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    trifluoperazine
    1 interaction

    Caution Advised

    ritonavir + trifluoperazine

    caution advised: combo may decr. trifluoperazine levels, efficacy (UGT induced)

  • tucatinib
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    tucatinib
    1 interaction

    Caution Advised

    ritonavir + tucatinib

    caution advised: combo may decr. tucatinib levels, efficacy (hepatic metabolism induced)

  • turmeric
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    turmeric
    1 interaction

    Caution Advised

    ritonavir + turmeric

    caution advised w/ oral turmeric: combo may decr. ritonavir levels, efficacy (P-gp-mediated transport induced)

  • vaborbactam
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vaborbactam
    3 interactions

    Caution Advised

    nirmatrelvir + vaborbactam

    caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism possibly induced)

    ritonavir + vaborbactam

    caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism possibly induced, P-gp-mediated transport possibly induced)

  • venlafaxine
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    venlafaxine
    1 interaction

    Caution Advised

    ritonavir + venlafaxine

    caution advised: combo may incr. venlafaxine levels, risk of adverse effects (hepatic metabolism inhibited)

  • vonoprazan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    vonoprazan
    1 interaction

    Caution Advised

    ritonavir + vonoprazan

    caution advised: combo may decr. vonoprazan levels, efficacy (hepatic metabolism induced)

  • voxilaprevir
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    voxilaprevir
    2 interactions

    Caution Advised

    ritonavir + voxilaprevir

    caution advised if ritonavir admin. w/ nirmatrelvir: combo may incr. voxilaprevir levels, risk of adverse effects (mechanism unknown, hepatic transport possibly inhibited)

  • zaleplon
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zaleplon
    1 interaction

    Caution Advised

    ritonavir + zaleplon

    caution advised: combo may incr. zaleplon levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • zileuton
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zileuton
    1 interaction

    Caution Advised

    ritonavir + zileuton

    caution advised: combo may incr. zileuton levels, risk of adverse effects (hepatic metabolism inhibited)

  • zolmitriptan
  • Paxlovid (nirmatrelvir and ritonavir)
    +
    zolmitriptan
    1 interaction

    Caution Advised

    ritonavir + zolmitriptan

    caution advised: combo may decr. zolmitriptan levels, efficacy (hepatic metabolism induced)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@12ba12af
  • hypersensitivity reaction
  • anaphylaxis
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • hepatotoxicity
  • hepatitis
  • jaundice

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@29806eff
  • dysgeusia
  • diarrhea

Safety/Monitoring .

Monitoring Parameters
no routine tests recommended

Pregnancy/Lactation .

Pregnancy

Clinical Summary

nirmatrelvir: weigh risk/benefit during pregnancy; inadequate human data available; possible risk of decr. fetal wt based on animal data at 10x recommended human dose

ritonavir: may use during pregnancy; no known risk of fetal harm based on human data

Lactation

Clinical Summary

weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@2f610477

Metabolism: for nirmatrelvir: liver; CYP450: 3A4 substrate; for ritonavir: liver; CYP450: 2D6 (minor), 3A4 (major) substrate

Excretion: for nirmatrelvir: feces 49.6% (55% unchanged), urine 35.3% (27.5% unchanged); Half-life: 6.1h; for ritonavir: feces 86.4% (33.8% unchanged), urine 11.3% (3.5% unchanged); Half-life: 6.2h

Subclass: Coronavirus

Mechanism of Action
for nirmatrelvir: inhibits SARS-CoV-2 main protease (Mpro), preventing viral replication; for ritonavir: inhibits CYP3A, boosting nirmatrelvir levels

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Pfizer Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@ed5da1c

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information